

Günther Hochhaus

Address: College of Pharmacy, Box 100494
University of Florida
Gainesville, Florida, 32610
Tel. (352) 273 7861; FAX (352) 392 4447
Hochhaus@UFL.Edu

Personal Data:

Place of Birth: Paderborn, Germany (12/12/1955)
Nationality: German
Marital Status: Married, 1984

Education:

1975-1979 Undergraduate Student in Pharmacy Westf. Wilhelms -
Universität, Münster, FRG
1979 State Examination in Pharmacy (B.Sc.)
1979-1980 Practical Pharmacy Education Elisabeth Apotheke,
Detmold, FRG
1980-1984 Graduate Studies at the Institute of Pharm. Chem. (Ph.D.)
1994 GLP Short Course

Positions held:

Oct. 1980 - Nov. 1984 Teaching Assistant for Pharm. Chemistry and
Biochemistry, Westf. Wilhelms Universitaet
Jan. 1985 - June 1987 Postdoctoral Research Pharmacologist Department of Pharm.
Chemistry, School of Pharmacy, Univ. of California, San
Francisco, Group Leader: Prof. Dr. W. Sadee
July 1987 - July 1992 Assistant Professor of Pharmacy, Department of
Pharmaceutics, University of Florida, Gainesville
July 1992-July 2001 Associate Professor of Pharmacy, University of Florida
July 1999-present Adjunct Faculty at the Engineering Research Center
July 2001-present Professor of Pharmacy, University of Florida

Professional Licensures: “Approbation Apotheker”, Muenster, 1983

Scientific/Professional Societies:
 Member of American Association of Pharmaceutical Scientists
 Member of American Association for the Advancement of Science
 Member of the European Federation for Pharmaceutical Sciences

Services to Scholarly and Professional Journals:

Professional Organizations: Regent of the American College of Clinical Pharmacology (1999-2005)
 Chairman, Honors & Award Committee, American
 College of Clinical Pharmacology (2000-2005)

Editorial Advisory Board: J. Clin. Pharmacol.
 AAPS PharmSci.
 Journal of Pharmacy and Pharmacology
 Pharmaceutical Research

Referee: J. Chromat., J. Pharmacokin. Biopharm., J. Pharmacol. Res., J.
 Pharm. Sci. J. Pharmaceut., Clin. Pharmacokin., Eur. J. Clin.
 Investigations, J. Allergy Clin. Immunology, J. Contr. Rel.

Major University Services: Health Center Institutional Review Board (until 1995)
 Member of the Health Center Student Conduct
 Standards Committee. Honary Degrees, UF
 Distinguished Alumni Awards and Memorials
 Committee (since 2003)

Awards: Young Investigator Award from the "Deutsche Gesellschaft für
 Atemwegs und Lungenforschung" (1991)
 Fellow of the American College of Clinical Pharmacology (1992)
 Tanabe Young Investigator Award of the American Association of
 Clinical Pharmacology (1998)
 Teaching Improvement Award of the Univ. of Florida (1998)
 Fellow of American Association of Pharmaceutical Scientists (2004)
 University of Florida Research Foundation Professorship (2006)

Teaching Experience: Responsible for pharmaceutical analysis courses on the graduate level, and the biopharmaceutics and pharmacokinetic class

Research Interests: PK/PD based Design and Evaluation of Pulmonary Delivery Systems for Asthma Drugs, Clinical Trial Simulations, Population pharmacokinetic Approaches
Pulmonary Peptide Delivery for Heroin Addiction

PUBLICATIONS

1. Identification of glucocorticoid receptors in normal and adult human lung. G. Hochhaus, P. Rohdewald, H. Möllmann, D. Greschuchna. *Res. Exp. Med.* 182, 71-78 (1983)
2. Comparison of the glucocorticoid receptor of the human lung with those of other human and bovine target organs. G. Hochhaus, P. Rohdewald, H. Möllmann, W.T. Ulmer. *Atemw.-Lungenkrkh.* 9, 281-283 (1983)
3. Receptor binding affinities of commercial glucocorticoids to the glucocorticoid receptor of human lung. P. Rohdewald, H. Möllmann, G. Hochhaus. *Atemw.-Lungenkrkh.* 10, 484-487 (1984)
4. Simultaneous determination of glucocorticoid alcohols, their succinates and hydrocortisone in plasma. P. Rohdewald, J. Rehder, G. Drehsen, G. Hochhaus, H. Derendorf, H. Möllmann. *J. Pharm. Biomed. Anal.* 3, 565-573 (1985)
5. Glucocorticoid receptors in the respiration tract. P. Rohdewald, H. Möllmann, K.M. Mueller, G. Hochhaus. In: *Bochumer Treff 1984, Rezeptoren und nervöse Versorgung des bronchopulmonalen Systems*, Verlag Gedon & Reuss, Muenchen, 223-242 (1985)
6. Affinities of glucocorticoids for glucocorticoid receptors in the human lung. P. Rohdewald, H. Möllmann, G. Hochhaus. *Agents and Action.* 17, 290-291 (1985)
7. HPLC determination of glucocorticoid alcohols, their phosphates and hydrocortisone in biological fluids. H. Derendorf, P. Rohdewald, G. Hochhaus, H. Möllmann. *J. Pharm. Biomed. Anal.* 4, 197-206 (1986)
8. Delta opiate receptors in human neuroblastoma cell lines. G. Hochhaus, V.C. Yu, W. Sadee. *Brain Res.* 382, 327-331 (1986)
9. Development of a biotin-avidin probe for detecting opiate receptors. G. Hochhaus, B.W. Gibson, W. Sadee. *NIDA Research Monographs.* 75, 33-36 (1987)
10. Biotinylated human β -endorphins as probes for the opiate receptor G. Hochhaus, B.W. Gibson, W. Sadee. *J. Biol. Chem.* 263, 92-97 (1988)
11. A biotin-avidin based enzyme immunoassay for β_h -endorphin. G. Hochhaus, W. Sadee. *Pharm. Res.* 5, 232-235 (1988)
12. Effects of opioid peptides on human neuroblastoma cells. W. Sadee, V.C. Yu, G. Hochhaus. *NIDA Research Monograph 87, Opioid peptides: an update.* Rao S. Rapaka, Bhola N. Dhawan (eds.). National Institute on Drug Abuse. (1988)

13. [Biocytin¹³]dynorphin A1-13 amide: a potential probe for the k-opioid receptor. G. Hochhaus, A. Patthy, R. Schwieter, D.V. Santi, W. Sadee. *Pharm. Res.* 5, 790-794 (1988)
14. Neuronal cell differentiation of human neuroblastoma cells by retinoic acid plus herbimycin-A1. P.N. Preis, H. Saya, L. Nadasdi, G. Hochhaus, V. Levin, W. Sadee. *Cancer Research.* 48, 6530-6534 (1988)
15. Differentiation of human neuroblastoma cells: marked potentiation of PGE1-stimulated accumulation of cyclic AMP by retinoic acid. V.C. Yu, G. Hochhaus, F-H. Chang, M.L. Richards, H. R. Bourne, W. Sadee. *J. Neurochem.* 51, 1892-1899 (1988)
16. Differential therapeutic aspects of the treatment of toxic gas poisoning with glucocorticoids. H.W. Möllmann, J. Barth, D. Schött, H. Derendorf, G. Hochhaus. *Intensivmed.* 26, 2-15 (1989)
17. An avidin/biotin based enzyme-linked Immunosorbent assay for dynorphin A1-13. G. Hochhaus, Lase Hu. *J. Pharm. Biomed. Anal.* 8, 541-545 (1990)
18. Binding affinities of rimexolone (ORG 6216), flunisolide and their putative metabolites for the glucocorticoid receptor of human synovial tissue. G. Hochhaus, H. Möllmann. *Agents and Actions.* 30, 377-380 (1990)
19. Absorption and transfer of water-soluble glucocorticoids through pulmonary membranes. J. Barth, A. Möllmann, G. Hochhaus, H. Derendorf, H.W. Möllmann. *Atemw.-Lungenkrkh.* 15, 412-416 (1989)
20. Oral bioavailability of triamcinolone tablets and a triamcinolone diacetate suspension. G. Hochhaus, M. Pörtner, J. Barth, H. Möllmann, P. Rohdewald. *Pharm. Res.* 7, 558-560 (1990)
21. Pharmaceutical biotechnology: A new graduate course at the University of Florida College of Pharmacy. H. Schreier, G. Hochhaus, R.J. Pranker, H. Derendorf, M.E. Brewster, R.A. Baughman. *Am. J. Pharm. Educ.* 54, 46-50 (1990)
22. Pharmacodynamic aspects of systemic glucocorticoid action (German). J. Barth, H. Möllmann, H. Derendorf, G. Hochhaus. In: Willert, Heuck (eds.), *New Results in Osteology*, Springer, Heidelberg, 533-541(1989)
23. Pharmacokinetic aspects of intra-articular glucocorticoid administration (German). H. Derendorf, H. W. Möllmann, P. Rohdewald, D. Strohsand, J. Barth, G. Hochhaus. In Willert, Heuck (eds.), *New Results in Osteology*, Springer, Heidelberg, 474-481, (1989)
24. Glucocorticoids for the intra-articular therapy: Pharmacodynamic characterization via receptor binding studies. G. Hochhaus, H. Möllmann, J. Barth. *Akt. Rheumatol.* 15, 66-69 (1990)
25. Distribution and aggregation of crystals in glucocorticoid suspensions (German). H.W. Möllmann, B. Armbruster, J. Barth, H. Derendorf, O.W. Flörke, G. Hochhaus, C.R. Möllmann, P. Rohdewald, E.W. Schmidt. *Akt. Rheumatol.* 15, 101-124 (1990)
26. Fluorescence immunoassay. S. Schulman, G. Hochhaus, H.T. Karnes. In W.R.G. Baeyens (ed.) *Luminescence Techniques in Chemical and Biochemical Analysis*. Marcel Dekker, New York, 341-380 (1990)
27. cAMP accumulation in opioid sensitive SH-SY5Y neuroblastoma cells is modified by estradiol and progesterone. A. Ratka, G. Hochhaus, R.N. Wissler, J.W. Simpkins. *Mol. Cell. Endo.* 78, 155-162 (1991)
28. Soft drugs 10: blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate. P. Druzgala, G. Hochhaus, N. Bodor. *J. Steroid Biochem.* 38, 149-154 (1991)

29. Glucocorticoid activity and structure activity relationships in a series of some novel 17 α -ether-substituted steroids: influence of 17 α -substituents. G. Hochhaus, P. Druzgala, R. Hochhaus, M-J. Huang, N. Bodor. *Drug Design and Discovery*. 8, 117-125 (1991)
30. Pharmacokinetic/pharmacodynamic correlation of pulmonary and cardiac effects of fenoterol in asthmatic patients after different routes of administration. G. Hochhaus, E.W. Schmidt, K.L. Rominger, H.W. Möllmann. *Pharm. Res.* 9, 291- 297 (1992)
31. A selective LC/RIA for dexamethasone and its prodrug dexamethasone-21-isonicotinate in biological fluids. G. Hochhaus, H. Derendorf, H. Möllmann, J. Barth. *J. Pharm. Biomed. Anal.* 9, 761-767 (1991)
32. A new fluorogenic assay for tyrosine-containing peptides. M. Tellier, R.J. Pranker, G. Hochhaus. *J. Pharm. Biomed. Anal.* 9, 557-563 (1991)
33. Pharmacokinetic evaluation of a new glucocorticoid soft drug: loteprednol etabonate. G. Hochhaus, L.S. Chen, A. Ratka, P. Druzgala, J. Howes, N. Bodor, H. Derendorf. *J. Pharm. Sci.* 81, 1210-1215 (1992)
34. A selective HPLC/RIA for dexamethasone and its prodrug dexamethasone-21-sulfobenzoate in biological fluids. G. Hochhaus, R. Hochhaus, G. Werber, H. Derendorf, H. Möllmann. *Biomedical Chromatography* 6, 283-286 (1992)
35. Analysis of shape, particle size distribution and aggregation of the crystals of intal aerosol, sodium cromoglycate, tilade aerosol and nedocromil sodium. J. Barth, H.W. Möllmann, W. Floerke, B. Armbruster, G. Hochhaus, H. Derendorf. *Eur. J. Hosp. Pharm.* 3, 20-28 (1993)
36. Receptor-based pharmacokinetic-pharmacodynamic analysis of corticosteroids. H. Derendorf, G. Hochhaus, H. Möllmann, J. Barth, M. Krieg, S. Tunn, C. Möllmann. *J. Clin. Pharmacol.* 33, 115-123 (1993)
37. Generic and alternative brand name pharmaceutical equivalents; substitute with caution! L. Hendeles, G. Hochhaus, S. Kazerounian. *Am. J. Hosp. Pharm.* 50, 323-329 (1993)
38. Studies on the pharmacokinetics and metabolism of prednicarbate after cutaneous and oral administration. J. Barth, H. Möllmann, K.H. Lehr, T. Höhler, H. Derendorf, G. Hochhaus. *Skin Pharmacol.* 6, 179-186 (1993)
39. Pharmacokinetics and pharmacodynamics of prednisolone after intravenous and oral administration. J. Barth, M. Damoiseaux, H. Möllmann, K.H. Brandis, G. Hochhaus, H. Derendorf. *Int. J. Clin. Pharmacol. Ther. Toxicol.* 30, 317-324 (1992)
40. PK/PD analysis of albuterol action: application to a comparative assessment of beta-2-adrenergic drugs. G. Hochhaus, L. Hendeles, E. Harmon, H. Möllmann. *Eur. J. Pharm. Sci.* 1, 73-80 (1993)
41. Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol . G. Hochhaus, H. Möllmann. *Int. J. Clin. Pharmacol. Ther. Toxicol.* 30,342-362 (1992)
42. Prednicarbate after different forms of administration: plasma levels of drug and metabolites and effects on endogenous cortisol levels in humans. J. Barth, G. Hochhaus, H. Derendorf, K.H. Lehr, T. Hoehler, H. Möllmann. *Curr. Probl. Dermatol.* 21, 147-156 (1993)
43. Topical use of steroids in gastroenterology. H.W. Möllmann, G. Hochhaus, A. Tromm, J. Barth, C. Bigalke, B. May, A.C. Möllmann, U. Schwegler, H. Derendorf, S. Tunn. In: Schoelmerisch, W. Kruis, H. Goebell, W. Hohenberger, V. Gross (eds.), *Inflammatory Bowel Diseases-Pathophysiology as Basis of Treatment*, Kluwer Academic Publishers, London, 343-349 (1993)
44. Immunoassay. H.T. Karnes, M. A. Sarkar, G. Hochhaus, S.G. Schulman. In: J. Swarbrickand, J.C. Boylan (eds.), *Encyclopedia of Pharmaceutical Technology*, Volume 8, Marcel Dekker, New York, 31-52 (1993)

45. Clinical pharmacology of pancreatic enzymes in patients with cystic fibrosis and in-vitro performance of microencapsulated formulations. M. Kraisinger, G. Hochhaus, A. Stecenko, E. Bowser, L. Hendeles. *J. Clin. Pharmacol.* 34, 158-166 (1994)
46. Bioavailability of hydrocortisone after single und multiple dosing of hydrocortisone foam in patients with distal chronic inflammatory diseases and healthy volunteers. T. Wagner, J. Barth, C. Bigalke, S. Tunn, M. Krieg. H. Derendorf, H. Möllmann, B. May, G. Hochhaus. *Aktuelle Koloproktologie* 10, 223-226 (1993)
47. Leucine enkephalin-tyrosinase reaction products: Identification by mass spectrometry and biological activity. V. Larsimont, L. Prokai, G. Hochhaus. *Biochim. Biophys. Acta* 1222, 95-100 (1994)
48. Pharmacokinetics of triamcinolone acetonide after IV, oral & inhaled administration . H. Derendorf, G. Hochhaus, S. Rohatagi, H. Möllmann, J. Barth, M. Erdmann. *J. Clin. Pharmacol.* 35, 302-305 (1995)
49. Response to commentary on pharmacokinetic characterization and tissue distribution of a new glucocorticoid soft drug loteprednol etabonate in rats and dogs. G. Hochhaus, P. Druzgala, J. Howes, N. Bodor, H. Derendorf. *J. Pharm. Sci.* 83, 1067-1068 (1994)
50. Assessment of glucocorticoid lung targeting by ex-vivo receptor binding studies. G. Hochhaus, R. Gonzales-Rothi, A. Lukyanov, H. Derendorf, H. Schreier, T. Dalla Costa. *Pharm. Res.* 12, 134-137 (1995)
51. Dose optimization based on pharmacokinetic/pharmacodynamic modeling. G. Hochhaus, H. Derendorf. In: H. Derendorf, G. Hochhaus (eds.), *Handbook of pharmacokinetic/ pharmacodynamic correlations*, CRC, New York, 79-120 (1995)
52. Pharmacokinetic-pharmacodynamic correlations of glucocorticoids, H. Möllmann, S. Balbach, G. Hochhaus, J. Barth, H. Derendorf. In: H. Derendorf, G. Hochhaus (eds.), *Handbook of pharmacokinetic/ pharmacodynamic correlations*, CRC, New York, 323-362 (1995)
53. Beta-agonists: terbutaline, albuterol, and fenoterol. G. Hochhaus, H. Möllmann. In: H. Derendorf, G. Hochhaus (eds.), *Handbook of pharmacokinetic/ pharmacodynamic correlations*, CRC, New York, 299-322 (1995)
54. Metabolism of dynorphin A1-13 in blood and plasma. S. Mueller, G. Hochhaus. *Pharm. Res.* 12, 1165-1170 (1995)
55. Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. H. Möllmann, G. Hochhaus, S. Rohatagi, J. Barth, H. Derendorf. *Pharm. Res.* 12, 1096-1100 (1995)
56. Problems with the equivalency of glucocorticoids. A comparison of the pharmacokinetics and pharmacodynamics of prednisolone and methylprednisolone (German). J. Barth, H. Möllmann, G. Hochhaus, H. Derendorf. *Dtsch. med. Wschr.* 119, 1671-1676 (1994)
57. Thermodynamic and kinetic aspects of the interaction of triamcinolone acetonide with liposomes. H. Schreier, A.N. Lukyanov, G. Hochhaus, R.J. Gonzalez-Rothi. *Proceed. Intern. Symp. Control. Rel. Bioact. Mater.* 21, 228-229 (1994)
58. Pulmonary targeting of liposomal triamcinolone acetonide phosphate. R. Gonzales-Rothi, S. Suarez, G. Hochhaus, H. Schreier, A. Lukyanov, H. Derendorf, T. Dalla Costa. *Pharm. Res.* 13, 1699-1703 (1996)
59. Pharmacokinetic interaction between endogenous cortisol and exogenous corticosteroids. S. Rohatagi, G. Hochhaus, H. Möllmann, J. Barth, H. Derendorf. *Pharmazie* 50, 610-613 (1995)

60. Concepts of corticosteroid therapy of chronic inflammatory bowel disease: topical vs. systemic administration H. Möllmann, J. Barth, G. Hochhaus, A. Möllmann, H. Derendorf, A. Tromm In "Corticosteroid therapy of chronic inflammatory bowel disease", B. May and H. Möllmann (eds.), Falk Foundation, 69-90 (1996)
61. Pharmacodynamic aspects of corticosteroid effects. G. Hochhaus, H. Derendorf, H. Möllmann, J. Barth, R. Hochhaus In "Corticosteroid therapy of chronic inflammatory bowel disease", B. May and H. Möllmann (eds.), Falk Foundation, 91-117 (1996)
62. Wechselseitige beziehungen zwischen pharmakokinetik und pharmakodynamik als grundlage einer rationalen therapie, H. Derendorf, H. Möllmann, G. Hochhaus, J. Barth, In "Glukokortikoidtherapie chronisch entzündlicher Darmerkrankungen" B. May and H. Möllmann (eds.), Falk Foundation, 119-135 (1996)
63. Pharmacokinetics and pharmacodynamics of budesonide-pH-modified release capsules, H. Möllmann, G. Hochhaus, A. Tromm, P. Froehlich, A. Möllmann, M. Krieg, H. Weisser, H. Derendorf, J. Barth In "Corticosteroid therapy of chronic inflammatory bowel disease", B. May and H. Möllmann (eds.), Falk Foundation, 149-167 (1996)
64. Pharmacodynamic aspects of glucocorticoid action, G. Hochhaus, H. Derendorf, H. Möllmann, J. Barth, R. Hochhaus. Kongressband, IV International Symposium of Inflammatory Bowel Diseases, Kluwer Academic Publishers Dordrecht, Boston, London, 61-79 (1996)
65. Pharmacokinetics and pharmacodynamics of cloprednol, H. Möllmann, G. Hochhaus, S. Rohatagi, J. Barth, H. Derendorf, M. Krieg, H. Weisser, A. Möllmann. *Int. J. Clin. Pharmacol. Ther.* 34, 1-5 (1996)
66. Kinetic/dynamic interrelationships as basis for rational therapy, H. Derendorf, H.W. Möllmann, G. Hochhaus, J. Barth, Kongressband, IV International Symposium of Inflammatory Bowel Diseases, B. May and H. Möllmann (eds.), Kluwer Academic Publishers, Dordrecht, Boston, London, 80-98 (1996)
67. Principles of topical versus systemic corticoid treatment in inflammatory bowel disease, H.W. Möllmann, J. Barth, G. Hochhaus, IV International Symposium of Inflammatory Bowel Disease, B. May and H. Möllmann (eds.), Kluwer, Academic Publishers, Dordrecht, Boston, London, 42-60 (1996)
68. Pharmacokinetics and pharmacodynamics of budesonide-pH modified release capsules, H.W. Möllmann, G. Hochhaus, A. Tromm, P. Froehlich, A.C. Möllmann, M. Krieg, H. Weisser, H. Derendorf, J. Barth, Kongressband, IV International Symposium of Inflammatory Bowel Diseases, B. May and H. Möllmann (eds.), Kluwer, Academic Publishers, Dordrecht, Boston, London, 107-120 (1996)
69. Pharmacokinetic and pharmacodynamic evaluation of triamcinolone acetonide after intravenous, oral and inhaled administration, S. Rohatagi, G. Hochhaus, H. Möllmann, J. Barth, E. Galia, M. Erdmann, H. Sourgens, H. Derendorf. *J. Clin. Pharmacol.* 35, 1187-1193 (1996)
70. Interspecies comparison of in-vitro plasma degradation of dynorphin A1-13. S. Mueller, R. Dunker, G. Hochhaus. *Die Pharmazie* 51, 581-585 (1996)
71. Metabolism of dynorphin A1-13 in human CSF, S. Mueller, B.L. Grundy, G. Hochhaus. *Neurochem. Res.* 21, 1213-1219 (1996)
72. Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model, G. Hochhaus, H. Derendorf, H. Möllmann, R. Gonzalez-Rothi. *J. Clin. Pharmacol.* 37, 881-892 (1997)
73. Pharmacokinetic/pharmacodynamic evaluation of systemic effects of flunisolide after inhalation, H. Möllmann, H. Derendorf, J. Barth, B. Meibohm, M. Wagner, M. Krieg, J. Knoeller, and G. Hochhaus. *J. Clin. Pharmacol.* 37, 893-903 (1997).

74. An HPLC/RIA method for dynorphin A1-13 and its main metabolites in human blood, S. Müller, B. Ho, P.L. Gambus, W. Millard, G. Hochhaus. *J. Pharm. Biomed. Anal.* 16, 101-109 (1997)
75. A selective HPLC/RIA for the determination of budesonide, G. Hochhaus, P. Froehlich, R. Hochhaus, A. Möllmann, H. Derendorf, H.W. Möllmann. *J. Pharm. Biomed. Anal.*, 17, 1235-1242 (1998)
76. Displacement of [³H]-L-glutamate in rat brain membranes by metabolic dynorphin fragments, S. Mueller, F. B. Chang-Sing-Pang, and G. Hochhaus, *Die Pharmazie*, 53, 142-143 (1998)
77. The pharmacokinetics of i.v. dynorphin A (1-13) in opioid naive and opioid tolerant human volunteers, P.L. Gambus, T.W. Schnider, C.F. Minto, E. Youngs, V. Billard, G. Hochhaus, W.L. Brose, S.L. Shafer. *Clin. Pharmacol. Therapeutics*, 64, 27-38 (1998)
78. Pharmacodynamic aspects of drug delivery, H. Derendorf, G. Hochhaus. *Clin. Pharmacology 15: Aspekte der intestinalen Absorption und der Modellentwicklung in Pharmakokinetik und Pharmacodynamik*, ed. By T. Gramatte and M. Weiss, W. Zuckschwerdt Verlag, München, 10-18 (1998)
79. Pharmacokinetic and pharmacodynamic evaluation of fluticasone after inhaled administration, H. Möllmann, M. Wagner, B. Meibohm, G. Hochhaus, J. Barth, C. Falcoz, M. Wagner, H. Derendorf. *Eur. J. Clin. Pharmacol.*, 53, 459-467 (1998)
80. Pharmacokinetics of methylprednisolone and prednisolone after single and multiple oral dosing, S. Rohatagi, J. Barth, H. Möllmann, G. Hochhaus, A. Soldner, H. Derendorf. *J. Clin. Pharmacol.* 37, 916-925 (1997)
81. Dependency of cortisol suppression on the administration time of inhaled corticosteroids, B. Meibohm, G. Hochhaus, S. Rohatagi, H. Möllmann, J. Barth, M. Wagner, M. Krieg, R. Stöckmann, H. Derendorf. *J. Clin. Pharmacol.* 37, 704-710 (1997)
82. Clinical PK/PD modeling as a tool in drug development of corticosteroids, H. Derendorf, H. Möllmann, G. Hochhaus, B. Meibohm, J. Barth. *Int. J. Clin. Pharmacol. Therapeut.* 35, 481-488 (1997)
83. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. H. Derendorf, G. Hochhaus, B. Meibohm, H. Möllmann, J. Barth. *J. Allergy Clin. Immunol.* 101 S440-446 (1998)
84. Effect of dose and release rate pulmonary targeting of inhaled on pulmonary targeting of liposomal triamcinolone acetonide. S. Suarez, R.J. Gonzales-Rothi, H. Schreier, G. Hochhaus. *J. Pharm. Res.*, 15, 461-465 (1998)
85. Pulmonary selectivity of glucocorticoids: How is it influenced by formulation? G. Hochhaus, S. Suarez, R.J. Gonzales-Rothi, H. Schreier, *Respiratory Drug Delivery VI*, R. Dalby, P. Byron, S.J. Farr, eds, Interpharm Press, Buffalo Grove, IL, 45-52 (1998)
86. Pharmacokinetic and pharmacodynamic aspects of salmeterol therapy, A. Buchwald, G. Hochhaus. *Int. J. Clin. Pharmacol. Therapeut.*, 36, 652-660 (1998)
87. The clinical pharmacology of fluticasone propionate. B. Meibohm, H. Möllmann, M. Wagner, G. Hochhaus, A. Möllmann, H. Derendorf. *Rev. Contemp. Pharmacother.* 8, 535-549 (1998)
88. Salmeterol, langwirkendes inhalatives β_2 -Sympathomimetikum, G. Hochhaus, Amy Buchwald, M. Schulz. *Pharmz. Zeit.* 143, 2318-2324 (1998)
89. Formoterol, langwirkendes inhalatives β_2 -Sympathomimetikum, G. Hochhaus, Amy Buchwald, M. Schulz. *Pharmz. Zeit.* 143, 4354-4361 (1998)

90. A PK/PD approach to predict the cumulative cortisol suppression of inhaled corticosteroids, B. Meibohm, G. Hochhaus, H. Möllmann, J. Barth, M. Wagner, M. Krieg, R. Stöckmann, H. Derendorf. *J. Pharmacokin. Biopharm.*, 27, 127-147 (1999)
91. Analysis of leucine-enkephalin by HPLC using enzymatic derivatization by tyrosinase and electrochemical or fluorescence detection, V. Larsimont, M. Bogaards, P. Mulleneers, G. Hochhaus. *J. Pharm. Biomed. Anal.*, 19, 855-864 (1999)
92. Mechanism based PK/PD-model for the lymphocytopenia induced by endogenous and exogenous corticosteroids. B. Meibohm, H. Derendorf, H. Möllmann, P. Fröhlich, A. Tromm, M. Wagner, M. Krieg, G. Hochhaus. *Int. J. Clin. Pharmacol. Therapeut.*, 37, 367-376 (1999)
93. Assessment of complex peptide degradation pathways via structured multi-compartmental modeling approaches: the metabolism of dynorphin A1-13 and related fragments in human plasma, S. Müller, A. Hutson, V. Arya, G. Hochhaus. *J. Pharm. Sci.*, 88, 938-944 (1999)
94. Kinetic modeling of plasmid DNA degradation in rat plasma. B.E. Houk, G. Hochhaus, J.A. Hughes. *AAPS PharmSci.* 1, issue 4 (1999)
95. Pharmacokinetic considerations in the design of pulmonary drug delivery systems for glucocorticoids. C. Mobley, G. Hochhaus. In: H. Schreier (ed.), *Drug Targeting Technology*, Marcel Dekker, New York, 51-83 (2001)
96. Pharmacokinetics and pharmacodynamics of dexamethasone sodium-m-sulfobenzoate (DS) after intravenous and intramuscular administration: a comparison with Dexamethasone Phosphate (DP). G. Hochhaus, J. Barth, S. Al-Fayoumi, S. Suarez, H. Derendorf, R. Hochhaus, H. Möllmann. *J. Clin. Pharmacol.* 41:425-434 (2001)
97. Nano-thin coatings for improved lung targeting of glucocorticoid dry powders: In-vitro and In-vivo characteristics. J. Talton, J. Fitz-Gerald, R. Singh, G. Hochhaus. *Respiratory Drug Delivery VII*, R. Dalby, P. Byron, S.J. Farr, eds, Interpharm Press, Buffalo Grove, IL, 67-74 (2000)
98. Loteprednol etabonate: a soft steroid for the treatment of allergic diseases in the airways. I. Szelenyi, G. Hochhaus, S. Heer, S. Küsters, D. Marx, H. Poppe, J.Engel. *Drugs of Today*, 36, 313-320 (2000)
99. Factors involved in the pulmonary targeting of inhaled glucocorticoids: the use of pharmacokinetic/dynamic simulations. G. Hochhaus, H. Derendorf, J. Talton, H. Moellmann. *Inhaled Steroids in Asthma, Lung Biology in Health and Disease*, Volume 163, R.P. Schleimer, P.M. O'Byrne, S.J. Szeffler, R. Brattsand. (eds); Marcel Dekker, New York, 283-305 (2001)
100. Systemic disposition and effects of inhaled corticosteroids. H. Derendorf, G. Hochhaus, S. Krishnaswami. *Inhaled Steroids in Asthma, Lung Biology in Health and Disease*, Volume 163, R.P. Schleimer, P.M. O'Byrne, S.J. Szeffler, R. Brattsand. (eds); Marcel Dekker, New York, 247-270 (2001)
101. A sensitive LC-MS/MS method for the quantification of fluticasone propionate in human plasma. S. Krishnaswami, H. Möllmann, H. Derendorf, G. Hochhaus. *J. Pharm. Biomed. Analysis* 22, 123-129 (2000)
102. Methods to assess pulmonary deposition and absorption of drugs. C. Mobley, G. Hochhaus. *Drug Discovery Today*, 6:367-375 (2001)
103. Evolution of pharmacokinetics and pharmacokinetic/dynamic correlations during the 19th century. G. Hochhaus, J. Berratt, H. Derendorf. *J. Clin. Pharmacol.* 40, 908-917 (2000)
104. Pharmacokinetic modeling of plasmid DNA degradation in rats. B.E. Houk, G. Hochhaus, J.A. Hughes. *Pharm. Res.* 18:67-74 (2001).

105. Fluticasone propionate: first long acting inhaled corticosteroid-analysis of clinical studies based on its pharmacokinetic profile. M. Wagner, R. Stöckmann, AC Möllmann, G. Hochhaus, H. Derendorf, J. Barth, HW Moellmann. *Atemwegs uund Lungenerkrankungen*, 25, 580-598 (1999)
106. Optimized therapeutic ratio of inhaled corticosteroids using retrometabolism. H. Derendorf, G. Hochhaus, S. Krishnaswami, B. Meibohm, H. Möllmann, *Pharmazie* 55, 223-227 (2000).
107. An interactive algorithm for the assessment of cumulative cortisol suppression during inhaled corticosteroid therapy. S. Krishnaswami, G. Hochhaus, H. Moellmann, H. Derendorf. *AAPS PharmSci*, 2, article 22 (<http://www.pharmsci.org/>)
108. Evaluation of pulmonary absorption using pharmacokinetic methods. H. Derendorf, G. Hochhaus, H. Moellmann. *J. Aerosol Med.* 14, Suppl.1, S9-S18 (2001)
109. Pharmacokinetics and rectal bioavailability of hydrocortisone acetate after single and multiple administration in healthy subjects and patients. A. Tromm, H. Moellmann, J. Barth, G. Hochhaus, M. Krieg, C. Bigalke, A. Moellmann, H. Derendorf. *J. Clin. Pharmacol.* 41 536-541 (2001)
110. Single dose and steady state pharmacokinetic and pharmacodynamic evaluation of therapeutically equipotent doses of inhaled fluticasone propionate and budesonide in healthy subjects. H. Möllmann, M. Wagner, S. Krishnaswami, H. Dimova, Y. Tang, C. Falcoz, P.T. Daley-Yates, M. Krieg, R. Stöckmann, J. Barth, A.C. Möllmann, H. Derendorf, G. Hochhaus. *J Clin Pharmacol*, 41, 1329-1338 (2001)
111. Systemic Disposition and Effects of inhaled Corticosteroids. , H. Derendorf, G. Hochhaus, S. Krishnaswami, H. Moellmann. *Inhaled Steroids in Asthma, Lung Biology in Health and Disease, Volume 163*, R.P. Schleimer, P.M. O'Byrne, S.J. Szeffler, R. Brattsand. (eds); Marcel Dekker, New York, 247-272 (2001)
112. Current concepts in pharmacokinetics and their implications for clinical medicine. M. Mueller, G. Hochhaus, H. Derendorf. *Wien.Klin.Wochenschr.* 15/16: 566-572 (2001)
113. Fluticasone propionate plasma concentrations after a metered-dose inhaler in children. O. Bessmertny, J. Liang, G. Hochhaus, S. Chesrown, L. Hendeles. *J. Pediatr. Pharmacol. Ther.* 6, 212-217 (2001)
114. Receptor binding studies of soft anticholinergic agents. F. Huang, P. Buchwald, C.E Browne, H.H. Farag, W. Wu, G. Hochhaus, N.Bodor. *AAPS PharmSci*, 3, article 30, 2001 (<http://www.pharmsci.org>)
115. A New Solution Based Intranasal Triamcinolone Acetonide Formulation In Patients With Perennial Allergic Rhinitis: How Does The PK/PD Profile For Cortisol Suppression Compare With An Aqueous Suspension Based Formulation? G. Hochhaus, M. A. Gonzalez, J. Shilstone, J. Karafilidis. *J. Clin Pharmacol.* 42:662-669 (2002)
116. SPE/RIA vs LC/MS for the measurement of low levels of budesonide in plasma. H. Dimova, Y. Wang, S. Pommery, H. Möllmann, G. Hochhaus. *Biomedical Chromatography* 17, 14-20 (2003)
117. In-Vitro deposition of fluticasone aerosol from a metered-dose inhaler with and without two common valved holding chambers. MJ Asmus , J. Liang , I. Coowanitwong , R Vafadari, G. Hochhaus. *Annals of Allergy, Asthma, & Immunology* 88:204-208 (2002)
118. Differences in inhaled fluticasone bioavailability between holding chambers in children with asthma. J. Liang, M.J Asmus., G. Hochhaus, S. Chesrown, L. Hendeles. *Pharmacotherapy.* 2002;22, 947-953 (2002)

119. Performance of a corticosteroid inhaler with a spacer fashioned from a plastic cold-drink bottle: Effect of changing bottle volume. S.A. Taylor, M..J Asmus , J. Liang , I. Coowanitwong , R. Vafadari, G. Hochhaus. *J Asthma* 40, 237-242 (2003)
120. Intranasal glucocorticoid delivery competition between local and systemic effects. G. Hochhaus, S. Sahasranaman, H. Derendorf, H. Moellmann. *S.T.P. Pharma Sciences* 12, 23-31 (2002)
121. In-vitro and in-vivo anti-inflammatory activity of ciclesonide, a novel on-site activated glucocorticoid. M. Stoeck, R. Rieder, G. Hochhaus, D. Haefner, J.M. Masso, A. Hatzelmann, D. Marx, D. S. Bundschuh. *JPET*. 309, 249-258 (2004)
122. Population pharmacokinetics and pharmacodynamics of ciclesonide. S. Rohatagi, V. Arya, K. Zech, R. Nave, .JS. Barrett, G. Hochhaus, BK Jensen and J.S. Barrett, *J. Clin. Pharmacol.*, 43, 365-378 (2003)
123. Pharmacokinetics of the dietary supplement creatine. A. Persky, G. Brazeau, G. Hochhaus. *Clin. Pharmacokinetics* 42, 557-574 (2003)
124. Validation of a simple liquid chromatography assay for creatine suitable for pharmacokinetic applications, determinations of plasma protein binding and verification of percent labeled claim of various creatine products.. A. Persky, G. Hochhaus, G. Brazeau. *J. Chromatography B* 794, 157-165 (2003)
125. Single and multiple dose pharmacokinetics of creatinine. A. Persky, M. Müller, H. Derendorf, M. Grant, G. Brazeau, G. Hochhaus. *J Clin. Pharmacol.* 43: 29-37 (2003)
126. Simultaneous quantification of budesonide, and its two metabolites, 6 β -hydroxybudesonide and 16 α -hydroxyprednisolone, in human plasma by liquid chromatography electrospray ionization tandem mass spectrometry. Y. Wang, Y. Tang, H. Moellmann, G. Hochhaus. *Biomedical Chromatography* 17, 158-163 (2003)
127. Pharmacokinetic and pharmacodynamics of drugs delivered to the lungs. M. Issar, C. Mobley, P. Khan, G. Hochhaus. In: *Pharmaceutical Inhalation Aerosol Technology*, second edition. A. Hickey (ed), 215-252, 2003, Marcel Dekker, New York.
128. Pharmacokinetic/pharmacodynamic modeling of total lymphocytes and selected subtypes after oral budesonide. J. Stark, S. Werner, S. Homrighausen, H. Derendorf, H. Moellmann, G. Hochhaus. *J. Pharmacokin. Pharmacodyn* 33:441-459 (2006)
129. Laser based synthesis of nanofunctionalized particulates for pulmonary based controlled drug delivery application. R.K. Singh, W.-S. Kim, M. Ollinger, V. Craciun, I Coowanitwong, G. Hochhaus, N. Koshizaki. *Applied Surface Science*, 197-198, 610-614 (2002)
130. Pharmacokinetics and pharmacodynamics of omalizumab (Xolair[®]): implications for clinical efficacy and dosing. G. Hochhaus, L. Brookman, Y. Deniz, H. Fox. *Current Medical Research and Opinion*, 19, 491-498 (2003)
131. In vitro performance of two common valved holding chamber with a chlorofluorocarbon-free beclomethasone metered-dose inhaler. Asmus MJ, Kwon SH, Coowanitwong I, Khorsand N, Hochhaus G. *Pharmacotherapy*. 23, 1538-1544 (2003).
132. Pharmacokinetic aspects of biotechnology products. L. Tang, A. Persky, G. Hochhaus, B. Meibohm, J. *Pharm. Sci.* 9, 2184-2204 (2004).
133. Drugs used in the treatment of opioid tolerance and physical dependence. K. Raith, G. Hochhaus. *Int. J. Clin. Pharmacol*, 42, 191-203 (2004)

134. In-vitro performance characteristics of valved holding chamber and spacer devices with a fluticasone metered-dose inhaler. Liang J, Coowanitwong I, Hochhaus G, Asmus MJ. *Pharmacotherapy* 24, 159-166 (2004).
135. Simultaneous quantification of beclomethasone dipropionate and its metabolite, beclomethasone 17-monopropionate in rat plasma and different tissues by liquid chromatography positive electrospray ionization tandem mass spectrometry. Y Wang, G. Hochhaus. *J Chromatography B* 805, 203-210 (2004).
136. Characterization of degradation products of mometasone furoate. S. Sahasranaman, M. Issar, G. Toth, G. Horvath, G. Hochhaus. *Die Pharmazie* 59, 367-373 (2004)
137. Metabolism of dynorphin A(1-13). B. Brugos, G. Hochhaus. *Die Pharmazie* 59, 339-343 (2004)
138. New Developments for corticosteroids. G. Hochhaus. *Proc Am Thorac Soc* 1, 269- 274 (2004)
139. Optimizing pharmaceutical properties of inhalation drugs. G. Hochhaus. *Respiratory Drug Delivery IX*, R. Dalby, P. Byron, J. Peart, J.D. Suman, S.J. Farr, eds, Davis Healthcare International Publishing, Raleigh, NC, Volume 1, 59-67 (2004)
140. Intranasal loteprednol etabonate in healthy male subjects: Pharmacokinetics and effects on endogenous cortisol. R. Hermann, M. Locher, M. Siebert-Weigel, N.La Vallee, H. Derendorf, G. Hochhaus. *J. Clin. Pharmacol.*, 44, 510-519 (2004)
141. Age effects on the pharmacokinetics of tityustoxin from *Tityus serrulatus* scorpion venom in rats. E.A. Nunan, V. Arya, G. Hochhaus, V.N. Cardoso, T. Moraes-Santos. *Braz. J. Med. Res*, 37, 385-390 (2004)
142. Possibilities in improvement of glucocorticoid treatments in asthma with special reference to loteprednol etabonate. I. Szelenyi, R. Hermann, G. Hochhaus, A. Pahl. *Die Pharmazie* 59, 409-411 (2004)
143. Identification of stabilized dynorphin derivatives for suppressing tolerance in morphine dependent rats. S. I. Al-Fayoumi, B. Brugos, V. Arya, E. Mulder, B. Epple, A. Mauderli and G. Hochhaus. *Pharm Res* 21, 1450-1456 (2004)
144. Stabilized dynorphin derivatives for modulating antinociceptive activity in morphine tolerant rats: Effect of different routes of administration. B. Brugos, Vikram Arya, Guenther Hochhaus. *AAPS J.* 2004; 6, article 36(4); www.aapsj.org
145. Brain permeability of inhaled corticosteroids. V. Arya, M. Issar, Y. Wang, J. D. Talton, G. Hochhaus. *JPP* 57, 1159-1168 (2005)
146. Contrary to adult, neonatal rats show pronounced brain uptake of corticosteroids. V. Arya, V. DeMarco, M. Issar, G. Hochhaus. *Drug Metab Dispos* 34;939-42 (2006).
147. A novel method for polymer coating of plasmid DNA: Initial investigations into the use of pulsed laser deposition and gene delivery. H. Coulen, J. Hughes, J. Talton, G. Hochhaus. *J. Drug Targeting* 12, 237-241 (2004)
148. Evaluation of oral budesonide in the treatment of active distal ulcerative colitis: Influence of the dosing regimen on pharmacokinetics, clinical efficacy and safety. H.H. Kolkman, H.W Moellmann, A.C. Moellmann, AS Pena, R. Greinwald, H.-D. Tauschel, G. Hochhaus. *Drugs of Today*, 40, 589-601 (2004)
149. How the lung handles drugs pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J. Winkler, G. Hochhaus, H. Derendorf. *Proc Am Thorac Soc* 1, 356-363 (2004)

150. Pharmacokinetic-pharmacodynamic evaluation of inhalation drugs: application to targeted pulmonary delivery systems using inhaled glucocorticoids as the main example. Z. Tayab, G. Hochhaus. *Expert opinions on drug delivery* 2, 519-532 (2005)
151. A sensitive liquid chromatography–tandem mass spectrometry method for the quantification of mometasone furoate in human plasma. S. Sahasranaman, Y. Tang, D. Biniasz, G. Hochhaus. *J Chromatography B* 819, 175-179 (2005)
152. Do Intensive Care Patients Need to Receive an Individualized Dosing Regimen for Levofloxacin? Z. Tayab, G. Hochhaus, S. Kaufmann, D. Jäger, J. Barth. *Int. J. Clin. Pharmacol. Ther.* 44: 262-9 (2006)
153. Differences in the Glucocorticoid to Progesterone Receptor Selectivity of Inhaled Glucocorticoids M. Issar, S. Sahasranaman, P. Buchwald, G. Hochhaus. *Eur. Resp. J.* 27, 511-516 (2006)
154. Interpretation of absorption rate data for inhaled fluticasone propionate obtained in compartmental pharmacokinetic modeling. S. Krishnaswami, G. Hochhaus, H. Moellmann, J. Barth, H. Derendorf. *Int J. Clin Pharmacol. Ther.* 43, 117-122 (2005)
155. Metabolism of Mometasone Furoate and Biological Activity of the Metabolites. S. Sahasranaman, M. Issar, G. Hochhaus. *DMD* 34: 225-233 (2006)
156. Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma, K. Mortimer, T.W. Harrison, Y.T. Kai Wu, S. Lewis, S. Sahasranaman, G. Hochhaus, A.E. Tattersfield. *Br. J. Clin. Pharmacol.* 62, 412-419 (2006)
157. Budesonide in previously untreated autoimmune hepatitis. J Wiegand, A Schuler, S Kanzler, A Lohse, U Beuers, W Kreisel, U Spengler, S Koletzko, PL Jansen, G Hochhaus, HW Moellmann, M Prols, MP Manns *Liver Int* 25:927-934 (2005).
158. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. M. Hubner, M., G. Hochhaus, , H. Derendorf, *Immunol Allergy Clin North Am*, 25, 469-488 (2005)
159. What is the best marker for inhaled corticosteroid safety? H. Derendorf, G. Hochhaus. *Allergy Asthma Proc* 26, 89-93 (2005).
160. Pharmacological effects of some newly developed soft anticholinergics and a receptor-binding QSAR study. N. Mori, P. Buchwald, W.-M. Wu, F. Ji, G. Hochhaus, N. Bodor. *Pharmazie* 61, 148-153 (2006)
161. Influence of the N-acetylation polymorphism on the metabolism of talampanel: an investigation in fasted and fed subjects genotyped for NAT2 variants. P. Buchwald, A. Juhasz, C. Bell, M. Patfalusi, P. Kovacs, G. Hochhaus, J. Howes, N. Bodor. *Pharmazie* 61, 125-34 (2006).
162. Lung bioavailability of hydrofluoroalkane fluticasone in young children when delivered by an antistatic chamber/mask. Y. Khan, Y. Tang, G. Hochhaus, J. J. Shuster, T. Spencer, S. Chesrown, L. Hendeles, *J. Pediatr.* 149, 793-797 (2006)
163. Pulmonary targeting of sustained release formulation of budesonide in neonatal rats. V. Arya, I. Coowanitwong, B. Brugos, W.-S. Kim, R. Singh, G. Hochhaus. *J. Drug Targeting* 14, 680-686 (2006)
164. Pharmacokinetic Evaluation of Dosage Forms for Colonic Delivery. G. Hochhaus. *Future Drug Delivery* 1, 49-51 (2006)

165. Advances in single-entity inhaled corticosteroid therapy. Z. Tayab, G. Hochhaus, *Allergy and Asthma Proceedings*, 28, 125-135 (2007)
166. What pharmacokinetic and pharmacodynamic properties are important for inhaled glucocorticoids? G. Hochhaus. *Annals of Allergy, Asthma, & Immunology* 98, S7-S15 (2007)
167. Pharmacokinetic/Pharmacodynamic Profile of Mometasone Furoate Nasal Spray: Potential Effects on Clinical Safety and Efficacy. G. Hochhaus. *Clin. Therapeutics* 30, 98-107 (2008).
168. Laser-ablated nanofunctional polymers for the formulation of slow-release powders for dry powder inhalers: physicochemical characterization and slow-release characteristics. I. Coowanitwong, G. Patel, W-S Kim, V. Craciun, J. R. Rocca, R. R. Singh, and G. Hochhaus. *J Pharmacy Pharmacol.* 59, 1473-1484 (2007)
169. Plasma levels of fluticasone and budesonide following inhalation: effect of bronchoconstriction. K. Mortimer, T.W. Harrison, Y.T. K. Wu, S. Lewis, S. Sahasranaman, G. Hochhaus, A.E. Tattersfield. *Br. J. Clin. Pharmacol.* 64, 439-444 (2007)
170. Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate. Z.R. Tayab, T.C. Fardon, D.K.C. Lee, K. Haggart, L.C. McFarlane, B.J. Lipworth, G. Hochhaus. *Br. J.* 64, 698-705 (2007)
171. Pharmacokinetic/pharmacodynamic factors and steroid sensitivity. G. Hochhaus. *Steroid Insensitivity*. Edited by B. Adcock (in press).
172. Slow release formulations of Inhaled Rifampin. *AAPS Journal* (in revision)
173. Simultaneous Determination of Dexamethasone, Dexamethasone 21-Acetate. N.Govan, G. Hochhaus. *J Liquid Chromatography* (in press)
174. Nasal Fluticasone Furoate Monography, N. Govin, G. Hochhaus, *Drugs of Today* (in press)
175. Relative receptor affinity comparisons among inhaled/intranasal corticosteroids: Perspectives on scientific pursuit and clinical relevance. G. Hochhaus, *J Respir. Research* (submitted)

ABSTRACTS PRESENTED AT MEETINGS

1. Identification of glucocorticoid receptors in normal and neoplastic human lung. G. Hochhaus, H. Möllmann, P. Rohdewald. Tagung der Gesellschaft fuer Lungen- und Atemwegforschung, Bochum (1982)
2. Affinity of glucocorticoids to their receptors in adult human lung. G. Hochhaus, H. Möllmann, P. Rohdewald. 35th meeting of the Academy of Pharmaceutical Sciences, Miami (1983)
3. Binding affinities of commercial glucocorticoids to the glucocorticoid receptor of the adult human lung. G. Hochhaus, P. Rohdewald, H. Möllmann, K.M. Mueller. 1. Gesamtkongress der pharmazeutischen Wissenschaften, Muenchen (1983)
4. Rezeptoraffinitäten handelsüblicher Glukokortikoide zum Glukokortikoid-Rezeptor der menschlichen Lunge. G. Hochhaus, P. Rohdewald, H. Möllmann G. Greschuchna, J. Barth, E.W. Schmidt. 31. Kongreß der Deutschen Gesellschaft für Pneumologie und Tuberkulose, Essen (1984)
5. Pharmakokinetische Wechselbeziehung intravenös applizierter Glukokortikoide in Serum und Lunge. J. Barth, H. Möllmann, E.W. Schmidt, P. Rohdewald, J. Rehder, G. Hochhaus. 31. Kongreß der Deutschen Gesellschaft für Pneumologie und Tuberkulose, Essen (1984)
6. Characterization of mu and delta opioid binding sites in a human neuroblastoma cell line. V. C Yu, M.L. Richards, G. Hochhaus, W. Sadee. International Narcotic Research Conference, North Falmouth, Massachusetts (1985)
7. Biotinylated β_n -endorphin derivatives as markers of the opiate receptors. G. Hochhaus, B.W. Gibson, W. Sadee. International Narcotics Research Conference, San Francisco, CA (1986)
8. Dynamics of receptor and second messenger regulation in human neuroblastoma cells. W. Sadee, V. C. Yu, G. Hochhaus. American Association of Pharmaceutical Scientists Annual Meeting, Washington D.C. (1986)
9. Second messengers of opioid and muscarinic receptors in human neuroblastoma cells. V.C. Yu, G. Hochhaus, W. Sadee. American Association of Pharmaceutical Scientists Annual Meeting, Washington, D.C. (1986)
10. Biotin labeled β_n -endorphin analogs as probes for the opiate receptor. G. Hochhaus, B.W. Gibson, W. Sadee. American Association of Pharmaceutical Scientists Annual Meeting, Washington D.C. (1986)
11. An avidin-biotin based enzyme-immunoassay for β -endorphin. G. Hochhaus, W. Sadee. American Association of Pharmaceutical Scientists Western Regional Meeting, Reno, NV (1988)
12. [Biocytin13]dynorphin A1-13 amide: a potential probe for the kappa opioid receptor. G. Hochhaus, A. Pathy, R. Schwietert, D.V. Santi, W. Sadee. American Association of Pharmaceutical Scientists Annual Meeting, Orlando, FL (1988)
13. Pharmacodynamic and mechanic interactions of locally administered glucocorticoid crystal suspensions. H. W. Möllmann, H. Derendorf, G. Hochhaus, J. Barth. 4th Annual Meeting of the German Society for Osteology, Göttingen (1989)
14. Pharmacodynamic interactions of systemic glucocorticoid therapy. J. Barth, H.W. Möllmann, H. Derendorf, G. Hochhaus. 4th Annual Meeting of the German Society for Osteology, Göttingen (1989)
15. Pharmacokinetic aspects of intra-articular administration of glucocorticoids. H. Derendorf, H.W. Möllmann, P. Rohdewald, D. Strohsband, J. Barth, G. Hochhaus, 4th Annual Meeting of the German Society for Osteology, Göttingen (1989)

16. Biopharmaceutical and pharmacological aspects of locally and systemically administered glucocorticoids. H. W. Möllmann, H. Derendorf, G. Hochhaus, J. Barth, 4th Annual Meeting of the German Society for Osteology, Göttingen (1989)
17. Comparison of the clinical pharmacodynamics of dexamethasone, methylprednisolone and triamcinolone acetonide. G. Hochhaus, H. Derendorf, H.W. Möllmann, C. Möllmann, M. Krieg, S. Tunn, J. Barth, H. J. Röthig. IV World Conference on Clinical Pharmacology and Therapeutics, Mannheim-Heidelberg (1989)
18. Time course of bronchospasmolytic effects after injection of different water-soluble glucocorticoids. H.W. Möllmann, J. Barth, H. Derendorf, G. Hochhaus. IV World Conference on Clinical Pharmacology and Therapeutics, Mannheim-Heidelberg (1989)
19. Transfer of different water-soluble glucocorticoids through the alveolar membrane. J. Barth, G. Hochhaus, H.W. Möllmann, P. Rohdewald. IV World Conference on Clinical Pharmacology and Therapeutics, Mannheim-Heidelberg (1989)
20. A sensitive enzyme-linked immunoassay for dynorphin A1-13. G. Hochhaus, L. Hu. American Association of Pharmaceutical Scientists Annual Meeting, Atlanta, Georgia (1989)
21. Pharmacodynamic profiles of fenoterol after different routes of administration. G. Hochhaus, E.W. Schmidt, H. Möllmann, W.T. Ulmer. American Association of Pharmaceutical Scientists Annual Meeting, Atlanta, Georgia (1989)
22. Bronchospasmolytic activity of methylprednisolone in patients with severe pulmonary obstruction. H. Möllmann, J. Barth, E.W. Schmidt, P. Rohdewald, H. Derendorf, G. Hochhaus. American Association of Pharmaceutical Scientists Annual Meeting, Atlanta, Georgia (1989)
23. Techniques for small peptides analysis: studies of pentigetide by capillary electrophoresis and immunoassay. S.-L. Chiang, K. Sasaki, T. Lobl, E. Morgan, S. Taylor, G. Hochhaus, J.L. Noone, T. Stolzer, M. Smith, J.C. Colburn. Eleventh American Peptide Symposium. San Diego CA (1989)
24. Pharmacokinetic and pharmacodynamic optimization of systemic glucocorticoid therapy in colitis. J. Barth, H.W. Möllmann, H. Derendorf, G. Hochhaus. Ulmer Symposium on Colitis, Ulm (1990)
25. Free peripheral compartment levels as interface between pharmacokinetics and pharmacodynamics of glucocorticoids. H. Derendorf, H. Möllmann, G. Hochhaus. 3rd Frontiers of Pharmacokinetics and Pharmacodynamics Symposium, Baltimore, Maryland (1990)
26. Pharmacokinetic-pharmacodynamic modeling of beta-adrenergic effects of fenoterol. G. Hochhaus, E.W. Schmidt, K.L. Rominger, H. Möllmann. 3rd Frontiers of Pharmacokinetics and Pharmacodynamics Symposium, Baltimore, Maryland (1990)
27. Clinical pharmacology of rectally administered glucocorticoids for Crohn's disease and colitis ulcerosa. H. Möllmann, J. Barth, D. Hüppe, H. Derendorf, G. Hochhaus. Ulmer Symposium on Colitis, Ulm (1990)
28. Clinical pharmacology of pharmacokinetics, intrinsic activity and biopharmaceutical properties of glucocorticoids after oral and intravenous administration. H. Möllmann, J. Barth, H. Derendorf, G. Hochhaus. Ulmer Symposium on Colitis, Ulm (1990)
29. Pharmacokinetic-pharmacodynamic modeling of beta-adrenergic effects of fenoterol after different routes of administration. G. Hochhaus. 23rd Annual Higuchi Research Seminar, Lake Ozark (1990)
30. An integrated pharmacokinetic-pharmacodynamic model for fenoterol. G. Hochhaus, E.W. Schmidt, K.L. Rominger, H. Möllmann. International Symposium on Measurement and Kinetics of *in-vivo* drug effect. Noordwijk (1990)

31. Glucocorticoid therapy for Crohn's disease and colitis ulcerosa. H. Möllmann, J. Barth, H. Derendorf, G. Hochhaus. Ulmer Symposium on Colitis, Ulm (1990)
32. Prediction of clinical potency of corticosteroids by pharmacokinetic-pharmacodynamic modeling. H. Derendorf, G. Hochhaus, H. Möllmann, J. Barth. Fifth Annual Meeting and Exposition of the American College of Clinical Pharmacology (ACCP), Las Vegas (1990). *J. Clin. Pharmacol.* 30, 835 (1990)
33. Area under the effect-time-curve as measure of cumulative drug effects. H. Derendorf, G. Hochhaus, H. Möllmann, J. Barth. American Association of Pharmaceutical Scientists. Annual Meeting, Las Vegas, Nevada (1990). *Pharm. Res.* 7, S-216 (1990)
34. Loteprenol etabonate: tissue distribution and receptor binding. G. Hochhaus, L.S. Chen, H. Derendorf, P. Druzgala, A. Ratka, American Association of Pharmaceutical Scientists. Annual Meeting, Las Vegas, Nevada (1990). *Pharm. Res.* 7, S-227 (1990)
35. Stability, opioid receptor binding and *in-vivo* evaluation of novel, brain specific redox carrier peptide systems. E. Brunt, G. Hochhaus, J. Sastry. American Association of Pharmaceutical Scientists. Annual Meeting, Las Vegas, Nevada (1990). *Pharm. Res.* 7, S-65 (1990)
36. Pharmacokinetics and pharmacodynamics of fenoterol. G. Hochhaus, E.W. Schmidt, K.L. Rominger, H. Möllmann. Fifth Annual Meeting and Exposition of the American College of Clinical Pharmacology (ACCP), Las Vegas (1990). *J. Clin. Pharmacol.* 30, 848 (1990)
37. A new class of anti-inflammatory glucocorticoids: soft analogs with 17α alkoxy side chains. P. Druzgala, G. Hochhaus, N. Bodor. Am. Chem. Society, Boston (1990)
38. Soft glucocorticoids: 17α -ether substitution and receptor binding. G. Hochhaus, R. Hochhaus, P. Druzgala, M-J. Huang, N. Bodor. American Association of Pharmaceutical Scientists. Southeast Region Meeting, Charleston (1991)
39. A sensitive assay for the simultaneous measurement of dexamethasone and dexamethasone-21-isonicotinate. G. Hochhaus, R. Hochhaus, H. Möllmann, C. Barmeyer, H. Derendorf. American Association of Pharmaceutical Scientists. Southeast Region Meeting, Charleston (1991)
40. Prediction of clinical potency of corticosteroids by pharmacokinetic pharmacodynamic modeling. H. Derendorf, G. Hochhaus, H. Möllmann, J. Barth. American Association of Pharmaceutical Scientists. Southeast Region Meeting, Charleston (1991)
41. Area under the effect-time curve as measure of cumulative drug effects. H. Derendorf, G. Hochhaus, H. Möllmann, J. Barth. American Association of Pharmaceutical Scientists. Southeast Region Meeting, Charleston (1991)
42. Dose optimization of corticosteroids. H. Derendorf, G. Hochhaus, H. Möllmann, J. Barth. The Southeastern Chapter of the American College of Clinical Pharmacology, Johnson City, TN (1990)
43. Systemic absorption of prednicarbate after dermal, oral and pulmonary administration. J. Barth, H.W. Möllmann, H. Derendorf, C. Möllmann, G. Hochhaus, K.H. Lehr, Th. Höler. XIth International Congress of Pharmacology. Amsterdam, The Netherlands (1990)
44. The nose as localization where bronchodilators act. E.W. Schmidt, G. Hochhaus, K.L. Rominger, H. Möllmann, W.T. Ulmer. 9th Congress of the European Society of Pneumology, London (1990)

45. Biopharmaceutical characterization of crystals in glucocorticoid suspension, J. Barth, H. Möllmann, J. Armbruster, O.W. Flörke, G. Hochhaus, H. Derendorf. Fifth Annual Meeting of the American Association of Pharmaceutical Scientists, Las Vegas (1990)
46. Differences in the profile of action and in the pharmacokinetics of fenoterol after nasal application and inhalation. E.W. Schmidt, G. Hochhaus, K.L. Rominger, H. Möllmann, W.T. Ulmer. *Pneumologie* 44,1038 (1990)
47. Clinical relevance of pharmacokinetic/dynamic and biopharmaceutical properties of glucocorticoids after oral, intravenous and rectal administration. H.W. Möllmann, J. Barth, H. Derendorf, G. Hochhaus, Glucocorticoids for the disease specific therapy of chronic inflammatory disorders, Cologne, Germany (1991)
48. Dose optimization using integrated pharmacokinetic/dynamic models. H. Derendorf, H.W. Möllmann, J. Barth, G. Hochhaus, Glucocorticoids for the disease specific therapy of chronic inflammatory disorders, Cologne, Germany (1991)
49. Pharmacodynamic interactions of glucocorticoids with inflammatory and immunological processes. J. Barth, H.W. Möllmann, H. Derendorf, G. Hochhaus, Glucocorticoids for the disease specific therapy of chronic inflammatory disorders, Cologne, Germany (1991)
50. Pharmacokinetics/pharmacodynamic model for fenoterol after different routes of administration E.W. Schmidt, G. Hochhaus, K.L. Rominger, H. Möllmann, W.T. Ulmer, *Klin. Wochenschr.* 69 (Suppl. XXIII), 166 (1991)
51. An integrated pharmacokinetic/pharmacodynamic model for beta2-adrenergic bronchodilators. E.W. Schmidt, G. Hochhaus, K.L. Rominger, H. Möllmann, W.T. Ulmer. 1st Annual Congress of the European Respiratory Society. Brüssel (1991)
52. Ultra-high doses of methylprednisolone in acute spinal cord injury: pharmacokinetic considerations. H. Möllmann, J. Barth, U. Bötel, G. Hochhaus, H. Derendorf, T. Wagner, 20th Annual Meeting of the American College of Clinical Pharmacology Atlanta (1991)
53. Effects versus side-effects : dose optimization based on an integrated pharmaco-kinetic/dynamic approach. G. Hochhaus, H. Derendorf, E.W. Schmidt, H. Möllmann, 20th Annual Meeting of the American College of Clinical Pharmacology, Atlanta (1991)
54. Receptor based pharmacokinetic-pharmacodynamic model for corticosteroids. H. Derendorf, G. Hochhaus, H. Möllmann, J. Barth. American Society for Clinical Pharmacology and Therapeutics, Orlando (1991)
55. Pharmacodynamic profiles of fenoterol after different routes of administration. E.W. Schmidt, G. Hochhaus, K.L. Rominger, H. Möllmann, W.T. Ulmer. American College of Chest Physicians, 57th Annual Scientific Assembly, San Francisco (1991)
56. A sensitive assay for the simultaneous measurement of dexamethasone and dexamethasone-21-isonicotinate. G. Hochhaus, R. Hochhaus, H. Möllmann, C. Barmeyer, H. Derendorf. American Association of Pharmaceutical Scientists, Washington DC (1991), *Pharm. Res.* 8, S-44 (1991)
57. New fluorescence assay of tyrosine containing peptides. M. Tellier, G. Hochhaus, R.J. Pranker. American Association of Pharmaceutical Scientists, Washington DC (1991), *Pharm. Res.* 8, S-24 (1991)
58. Glucocorticoid receptor binding affinity of novel soft steroids. E. Brunt, G. Hochhaus, N. Bodor. American Association of Pharmaceutical Scientists, Washington DC (1991), *Pharm. Res.* 8, S-80 (1991)

59. Soft glucocorticoids: 17 α -ether substitution and receptor binding. G. Hochhaus, P. Druzgala, M.-J. Huang, N. Bodor. American Association of Pharmaceutical Scientists, Washington DC (1991), Pharm. Res. 8, S-245 (1991)
60. Is there a dose with an optimal effect/side effect ratio? G. Hochhaus, H. Derendorf, H. Möllmann, E. Schmidt. American Association of Pharmaceutical Scientists, Washington DC (1991), Pharm. Res. 8, S-316 (1991)
61. Systemic absorption from hydrocortisone acetate rectal foam after single and multiple administration in healthy volunteers and patients with ulcerative colitis. J. Barth, H. Möllmann, S. Tunn, T. Wagner, H. Derendorf, G. Hochhaus. 11th Congress of the European Association of Internal Medicine, Lisbon (1991)
62. Comparative pharmacokinetics and pharmacodynamics of intravenously administered prodrugs for corticosteroids. H. Derendorf, G. Hochhaus, H. Möllmann, J. Barth. Japanese-U.S. Symposium on Drug Delivery, Maui (1991)
63. Glucocorticoid suspensions for sustained release delivery in orthopedics and rheumatology: factors modulating bioavailability. J. Barth, H. Möllmann, H. Derendorf, G. Hochhaus. Japanese-U.S. Symposium on Drug Delivery, Maui (1991)
64. Morphological properties, pharmacokinetics and local availability of intraarticularly administered glucocorticoid crystal suspension. J. Barth, H. Möllmann, H. Derendorf, G. Hochhaus. 98th Conference of the German Society of Internal Medicine, Wiesbaden (1992)
65. Bioactivity of a generic pancreatic enzyme in cystic fibrosis. L. Hendeles, J. Pedersen, E. Bowser, A. Stecenko, L. Molino, P. Toskes, H. Sitren, R. Cooper, G. Hochhaus, S. Kazerounian. ACCP, Orlando (1992)
66. Receptor based pharmacokinetic-pharmacodynamic model for corticosteroids. H. Derendorf, G. Hochhaus, H. Möllmann, J. Barth. Ninety-third Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Orlando (1991)
67. Comparative pharmacokinetics and pharmacodynamics on intravenously administered prodrugs for corticosteroids. H. Derendorf, G. Hochhaus, H. Möllmann. 1992 Southeast Regional Meeting of the American Association of Pharmaceutical Scientist, Wilmington (1992)
68. A sensitive assay for the simultaneous measurement of dexamethasone and dexamethasone-21-sulfobenzoate. G. Hochhaus, H. Derendorf, H. Möllmann, J. Barth, 1992 Southeast Regional Meeting of the American Association of Pharmaceutical Scientist, Wilmington (1992)
69. Receptor-binding affinities of novel soft steroids. G. Hochhaus, N. Bodor, E. Brunt. Southeast Regional Meeting of the American Association of Pharmaceutical Scientist, Wilmington (1992)
70. Is there a dose with an optimal effect/side effect ratio. G. Hochhaus, H. Derendorf, H. Möllmann. Southeast Regional Meeting of the American Association of Pharmaceutical Scientist, Wilmington (1992)
71. Clinical potencies of beta-2-agonists as assessed by a PK/PD approach. G. Hochhaus, L. Hendeles, L. Harmon, H. Möllmann. Southeast Regional Meeting of the American Association of Pharmaceutical Scientist, Wilmington (1992)
72. Bioactivity of a generic pancreatic enzyme in cystic fibrosis. L. Hendeles, J. Pedersen, E. Bowser, A. Stecenko, L. Molino, P. Toskes, H. Sitren, R. Cooper, G. Hochhaus. 13th Annual Meeting ACCP, Toronto, Canada (1992)

73. Suppression of the hypopituitary adrenal axis by a topical glucocorticoid of the non-fluorinated double ester type? G. Hochhaus. World Congress of Dermatology, Dermatology Symposium, Tarrytown (1992)
74. Molecular pharmacology of glucocorticoids. First Interdisciplinary Forum on Therapy Concepts for Glucocorticoids. G. Hochhaus, H. Möllmann, J. Barth, H. Derendorf. Darmstadt, Germany (1992)
75. Dose optimization for the therapy of glucocorticoids. First Interdisciplinary Forum on Therapy Concepts for Glucocorticoids. H. Derendorf, H. Möllmann, J. Barth, G. Hochhaus, Darmstadt, Germany (1992)
76. Pharmacodynamic interactions of glucocorticoids with inflammatory and immunological processes. J. Barth, H. Möllmann, G. Hochhaus, H. Derendorf. First Interdisciplinary Forum on Therapy Concepts for Glucocorticoids, Darmstadt, Germany (1992)
77. Pharmacokinetic/dynamic investigations of ultra-high doses of methylprednisolone in patients with acute spinal injury. H. Möllmann, J. Barth, G. Hochhaus, H. Derendorf, E. v. Winden, U. Bötzel. First Interdisciplinary Forum on Therapy Concepts for Glucocorticoids, Darmstadt, Germany (1992)
78. Bioactivity of a generic equivalent to pancrease MT16. L. Hendeles, E. Bowser, A. Stecenko, L. Molino, P. Toskes, R. Cooper, G. Hochhaus, S. Kazerounian. Pediatric Pulmonology, Suppl. 8, 311 (1992)
79. Pharmacokinetics and pharmacodynamics of prednisolone after intravenous and oral administration. H. Möllmann, M. Damoiseaux, J. Barth, K.-H. Brandis, G. Hochhaus, H. Derendorf. J. Clin. Pharmacol. 32, 750 (1992)
80. Clinical activities of selected beta-2-adrenergic drugs: A PK/PD based comparative approach. G. Hochhaus. L. Hendeles, H. Möllmann. J. Clin. Pharmacol. 32, 752 (1992)
81. Evaluation of pharmacokinetic interactions between prednisolone and hydrocortisone. S. Rohatagi, H. Möllmann, J. Barth. J. Clin. Pharmacol. 32, 756 (1992)
82. Use of ultra-high doses of methylprednisolone in acute spinal cord injury-steroid pharmacokinetics in plasma and cerebrospinal fluid, influence on adrenal cortisol and on some relevant blood parameters. J. Barth, G. Hochhaus, H.W. Möllmann, F. Schumann, U. Bötzel, E. v. Winden, H. Derendorf. 6th European Congress on Intensive Care Medicine. Barcelona, Spain (1992)
83. Analysis of hydrocortisone, prednisolone and methylprednisolone in biological fluids using normal phase chromatography S. Rohatagi, H. Möllmann, J. Barth, A. Soldner, G. Hochhaus, H. Derendorf 1993 Southeast Regional Meeting of the American Association of Pharmaceutical Scientists, Research Triangle Park (1993)
84. In-vitro plasma degradation of dynorphin A1-13. S. Müller, L. Prokai, G. Hochhaus. 1993 Southeast Regional Meeting of the American Association of Pharmaceutical Scientists, Research Triangle Park (1993)
85. Leucine enkephalin-tyrosinase reaction products-Identification and biological activity. V. Larsimont, L. Prokai, G. Hochhaus. 1993 Southeast Regional Meeting of the American Association of Pharmaceutical Scientists, Research Triangle Park (1993)
86. Pharmacokinetics and pharmacodynamics of budesonide after rectal application. H. Möllmann, A. Tromm, U. Schwegler, B. May, J. Barth, T. Wagner, H. Derendorf, G. Hochhaus. 9th Annual Meeting of the American Gastroenterological Association, Boston (1993)
87. Pharmacokinetics and pharmacodynamics of budesonide after oral topical administration. A. Tromm, H. Möllmann, U. Schwegler, B. May, J. Barth, H. Derendorf, G. Hochhaus. 9th Annual Meeting of the American Gastroenterological Association, Boston (1993)

88. Comparison of pharmacodynamic effects of 3 mg budesonide in healthy volunteers and patients with inflammatory bowel disease after ileostomy. H.W. Ecker, H. Möllmann, A. Tromm, W. Lindemann, J. Barth, H. Derendorf, G. Hochhaus, B. May. IV. International Symposium on Chronic Inflammatory Bowel Diseases, Strassburg (1993)
89. Mode of action of receptor mediated glucocorticoid action. G. Hochhaus IV. International Symposium on Chronic Inflammatory Bowel Diseases, Strassburg (1993)
90. Pharmacodynamics of budesonide after rectal application in healthy volunteers: evidence for low systemic side effects. H. Möllmann, A. Tromm, U. Schwengler, B. May, J. Barth, A. Wagner, S. Tunn, M. Krieg, H. Derendorf, G. Hochhaus. IV. International Symposium on Chronic Inflammatory Bowel Diseases, Strassburg (1993)
91. Plasma levels of budesonide after multiple oral administration of budesonide in healthy volunteers. H. Möllmann, A. Tromm, J. Barth, S. Tunn, M. Krieg, U. Schwengler, B. May, H. Derendorf, G. Hochhaus. IV. International Symposium on Chronic Inflammatory Bowel Diseases, Strassburg (1993)
92. Systemic effects of orally administered budesonide: comparison of a single and divided dose regimen. J. Barth, H. Möllmann, A. Tromm, S. Tunn, M. Krieg, U. Schwengler, B. May, H. Derendorf, G. Hochhaus. IV. International Symposium on Chronic Inflammatory Bowel Diseases, Strassburg (1993)
93. Pharmacokinetics and metabolic interactions of ultra-high dosed methylprednisolone in patients with acute spinal cord injury. U. Bötel, E. Gläser, J. Barth, R. Schumann, G. Hochhaus, H. Derendorf, S. Tunn, M. Krieg, C. Möllmann, H. Möllmann. 3rd Scientific Meeting of the Scandinavian Medical Society of Paraplegia, Lahti (1993)
94. Clinical significance of pharmacokinetic-pharmacodynamic modeling of corticosteroids. H. Derendorf, G. Hochhaus, H. Möllmann, J. Barth. World Congress of Pharmacy and Pharmaceutical Sciences FIP 1993, Tokyo (1993)
95. Oral treatment with budesonide in healthy volunteers: evidence of low systemic side effects. A. Tromm, H. Möllmann, U. Schwengler, B. May, J. Barth, H. Derendorf, G. Hochhaus. 22nd Annual Meeting of the American College of Clinical Pharmacology, Boston (1993)
96. Pharmacodynamics of budesonide after rectal application in healthy volunteers. H. Möllmann, A. Tromm, U. Schwengler, B. May, J. Barth, T. Wagner, H. Derendorf, G. Hochhaus. 22nd Annual Meeting of the American College of Clinical Pharmacology, Boston (1993)
97. New electrochemical and fluorogenic assays for leucine enkephalin based on enzymatic derivatization by tyrosinase. V. Larsimont, M. Bogaards, P. Mulleneers, G. Hochhaus. AAPS Eighth Annual Meeting, Orlando, Florida (1993). Pharm. Res. 10, S62 (1993)
98. In-vitro plasma degradation of dynorphin A1-13. S. Müller, L. Prokai, G. Hochhaus. AAPS Eighth Annual Meeting, Orlando, Florida (1993). Pharm. Res. 10, S92 (1993)
99. Pharmacokinetic and pharmacodynamic modeling of multiple dosing regimens of methylprednisolone and prednisolone. S. Rohatagi, H. Möllmann, J. Barth, A. Soldner, G. Hochhaus. AAPS Eighth Annual Meeting, Orlando, Florida (1993). Pharm. Res. 10, S384 (1993)
100. Oral treatment with budesonide: results of a pharmacodynamic study in health volunteers. A. Tromm., H. Möllmann, U. Schwengler, B. May, J. Barth, H. Derendorf, G. Hochhaus. AAPS Eighth Annual Meeting, Orlando, Florida (1993). Pharm. Res. 10, S385 (1993)
101. PK/PD based comparison of beta-2-adrenergic drugs. G. Hochhaus, L. Hendeles, H. Möllmann. AAPS Eighth Annual Meeting, Orlando, Florida (1993). Pharm. Res. 10, S385 (1993)

102. Leucine enkephalin tyrosinase reaction products-identification and biological activity. V. Larsimont, L. Prokai, G. Hochhaus. AAPS Eighth Annual Meeting, Orlando, Florida (1993). Pharm. Res. 10, S386 (1993)
103. Budesonide enemas and suppositories in healthy volunteers: evidence for low systemic side effects. H. Möllmann, A. Tromm, U. Schwegler, B. May, J. Barth, Th. Wagner, H. Derendorf, G. Hochhaus. AAPS Eighth Annual Meeting, Orlando, Florida (1993). Pharm. Res. 10, S387 (1993)
104. Pharmacokinetics of prednicarbate in humans after oral, pulmonary and cutaneous administration. J. Barth, G. Hochhaus, H. Derendorf, K. Lehr, T. Hoehler, H. Möllmann. AAPS Eighth Annual Meeting, Orlando, Florida (1993). Pharm. Res. 10, S389 (1993)
105. Receptor-based PK/PD model for corticosteroids. H. Derendorf, G. Hochhaus, S. Rohatagi, J. Barth, H. Möllmann. Second European Congress of Pharmaceutical Sciences, Berlin (1994). Eur. J. Pharm. Sci. 2, 92 (1994)
106. PK/PD characterization of pulmonary targeting. G. Hochhaus, R. Gonzalez-Rothi, E.W. Schmidt, H. Möllmann, H. Derendorf, T. Dalla Costa, H. Schreier. Second European Congress of Pharmaceutical Sciences, Berlin (1994). Eur. J. Pharm. Sci. 2, 102 (1994)
107. Pharmacokinetic and pharmacodynamic modeling of oral multiple dosing of methylprednisolone. S. Rohatagi, A. Soldner, J. Barth, H. Möllmann, G. Hochhaus, H. Derendorf. 23rd Annual Meeting of the American College of Clinical Pharmacology, Orlando (1994)
108. A novel method for analysis of budesonide and its metabolites in biological fluids. P. Froehlich, H. Derendorf, H. Möllmann, G. Hochhaus. 23rd Annual Meeting of the American College of Clinical Pharmacology, Orlando (1994)
109. Pharmacokinetic and pharmacodynamic modeling of oral multiple dosing of methylprednisolone. S. Rohatagi, A. Soldner, J. Barth, H. Möllmann, G. Hochhaus, H. Derendorf. 9th Annual Meeting of the American Association of Pharmaceutical Scientists, San Diego (1994). Pharm. Res. 11, S369 (1994)
110. Kinetic Evaluation of dynorphin A1-13 metabolism in human plasma *in vitro*. S. Müller, G. Hochhaus. 9th Annual Meeting of the American Association of Pharmaceutical Scientists, San Diego (1994). Pharm. Res. 11, S369 (1994)
111. Influence of endogenous hydrocortisone on pharmacokinetics and pharmacodynamics of exogenous corticosteroids. S. Rohatagi, E. Galia, G. Hochhaus, H. Derendorf. 9th Annual Meeting of the American Association of Pharmaceutical Scientists, San Diego (1994). Pharm. Res. 11, S369 (1994)
112. Pharmacokinetic and pharmacodynamic modeling of triamcinolone acetonide after intravenous, oral and pulmonary administration. S. Rohatagi, E. Galia, G. Hochhaus, H. Derendorf. 9th Annual Meeting of the American Association of Pharmaceutical Scientists, San Diego (1994). Pharm. Res. 11, S386 (1994)
113. Kinetic evaluation of the N-terminal metabolism of dynorphin A1-13 fragments in human plasma. S. Müller, G. Hochhaus. 9th Annual Meeting of the American Association of Pharmaceutical Scientists, San Diego (1994). Pharm. Res. 11, S410 (1994)
114. Clinical efficacy of beta-2-adrenergic drugs, A PK/PD approach. G. Hochhaus, L. Hendeles, E.W. Schmidt, H. Möllmann. Second European Congress of Pharmaceutical Sciences, Berlin (1994). Eur. J. Pharm. Sci. 2, 108 (1994)
115. A selective HPLC/RIA for budesonide in biological fluids. G. Hochhaus, P. Froelich, H. Derendorf, H. Möllmann, Second European Congress of Pharmaceutical Sciences, Berlin (1994). Eur. J. Pharm. Sci. 2, 153 (1994)

116. New electrochemical and fluorogenic assays for leucine enkephalin based on enzymatic derivatization by tyrosinase. V. Larsimont, M. Bogaards, P. Mulleneers, G. Hochhaus. Second European Congress of Pharmaceutical Sciences, Berlin (1994). *Eur. J. Pharm. Sci.* 2, 156 (1994)
117. Metabolism of Dyn A1-13 in human plasma. G. Hochhaus, S. Müller. Second European Congress of Pharmaceutical Sciences, Berlin (1994). *Eur. J. Pharm. Sci.* 2, 175 (1994)
118. PK/PD based assessment of pulmonary effects and systemic side effects after inhalation. G. Hochhaus. Southeastern Annual Meeting of the American Association of Pharmaceutical Scientists, Research Triangle Park (1995)
119. Pharmacokinetic aspects of liposomes. G. Hochhaus (invited speaker). Fourth International Liposome Meeting, Freiburg (1995)
120. Absorption from hydrocortisone after single and multiple rectal administrations of a hydrocortisone acetate foam preparation. H. Möllmann, J. Barth, M. Krieg, T. Wagner, H. Derendorf, and G. Hochhaus. Annual Meeting of AGAH, Neuss, (1995)
121. Pharmacokinetics and metabolism of prednicarbate after different routes of administration. J. Barth, H. Möllmann, H. Derendorf, C. Möllmann, G. Hochhaus, K. Lehr, and Th. Hohler. Annual Meeting of AGAH, Neuss, (1995)
122. Plasma levels and systemic effects after administration of budesonide enemas and foams. A. Möllmann, H. Möllmann, A. Tromm, G. Hochhaus, J. Barth, C. Bigalke, H. Derendorf, and B. May. Annual Meeting of AGAH, Neuss, (1995)
123. Glukokortikoid-Kristallsuspensionen für die intraartikuläre Applikation: Kristallmorphologie, Pharmakokinetik und lokale Wirkstoffkonzentration. J. Barth, H. Möllmann, H. Derendorf, and G. Hochhaus. Annual Meeting of AGAH, Neuss, (1995)
124. Pulmonary targeting: is it really possible? G. Hochhaus, 28th Annual Higuchi Research Seminar, (1995)
125. Pharmacokinetic/dynamic model for budesonide after oral delivery of pH modified release capsules (Budenofalk). G. Hochhaus, H. Möllmann, A. Tromm, J. Barth, A. Möllmann, M. Krieg. *J. of Gastroenterology and Hepatology*, Abstracts First International Conference of Gastroenterology Hong Kong/Shanghai, (1995)
126. Pharmacokinetic and pharmacodynamics of budesonide after oral application of budesonide modified-release capsules in ileostoma patients. H. Möllmann, A. Tromm, J. Barth, C. Bigalke, A. Möllmann, K. Ecker, S. Lindemann, A. Ewe, H. Derendorf, G. Hochhaus. *J. of Gastroenterology and Hepatology*, Abstracts First International Conference of Gastroenterology Hong Kong/Shanghai, (1995)
127. Pharmacokinetics of budesonide after oral delivery of pH modified release capsules (budenofalk) in healthy volunteers and patients with Crohn's disease and ileostoma. H. Möllmann, G. Hochhaus, A. Tromm, H. Derendorf, A. Möllmann, J. Barth, K. Ecker, A. Lindemann. *J. of Gastroenterology and Hepatology*, Abstracts First International Conference of Gastroenterology Hong Kong/Shanghai, (1995)
128. Systemic absorption from hydrocortisone acetate rectal foam after single and multiple administration in healthy subjects and patients with distal ulcerative colitis. J. Barth, H. Möllmann, A. Tromm, C. Bigalke, H. Derendorf, G. Hochhaus. *J. of Gastroenterology and Hepatology*, Abstracts Thirst International Conference of Gastroenterology Hong King/Shanghai, (1995)

129. Liposomes as a targeted drug delivery system to the lungs. R. Gonzalez-Rothi, S. Suarez, A. Lukyanov, H. Derendorf, H. Schreier, T. Dalla Costa and G. Hochhaus. 10th Annual Meeting of the American Association of Pharmaceutical Scientists, Miami (1995), Pharm. Res. 12 Suppl. 314 (1995)
130. PK/PD based assessment of pulmonary effects and systemic side effects after inhalation. G. Hochhaus. 10th Annual Meeting of the American Association of Pharmaceutical Scientists, Miami (1995), Pharm. Res. 12 Suppl. 314 (1995)
131. Optimizing dosing time of systemic corticosteroid administration using PK/PD modeling. S. Rohatagi, G. Hochhaus, and H. Derendorf. 10th Annual Meeting of the American Association of Pharmaceutical Scientists, Miami (1995), Pharm. Res. 12 Suppl. 367 (1995)
132. Receptor based integrated pharmacokinetic and pharmacodynamic modeling of corticosteroids after single and multiple administration. S. Rohatagi, H. Möllmann, J. Barth, G. Hochhaus, and H. Derendorf. 10th Annual Meeting of the American Association of Pharmaceutical Scientists, Miami (1995), Pharm. Res. 12 Suppl. 370 (1995)
133. Pharmacokinetics and pharmacodynamics of cloprednol. S. Rohatagi, H. Möllmann, J. Barth, G. Hochhaus and H. Derendorf, #PDDM8335, Pharm. Res. 12 Suppl. 410 (1995)
134. Pharmacokinetic and pharmacodynamic modeling of budesonide after single and multiple oral administration. P. Fröhlich, H. Möllmann, H. Derendorf and G. Hochhaus. 10th Annual Meeting of the American Association of Pharmaceutical Scientists, Miami (1995), Pharm. Res. 12(9) Suppl. 413 (1995)
135. Displacement of 3H-L-glutamate in rat brain membranes by metabolic dynorphin fragments. S. Müller, S. Al-Fayoumi, F. Chang-sing-Pang and G. Hochhaus. 10th Annual Meeting of the American Association of Pharmaceutical Scientists, Miami (1995), Pharm. Res. 12(9) Suppl. 349 (1995)
136. Plasma levels and pharmacodynamic effects of budesonide tablets and pH-modified-release capsules. Results of a comparative study in healthy volunteers. A. Tromm, H. Möllmann, J. Barth, G. Hochhaus, and H. Derendorf, Annual Meeting of AGAH, Neuss, (1995)
137. Pharmakokinetik/-dynamik - vergleich der wasserloeslichen dexamethasonester dexamethason-21-sulfobenzoate und dexamethasonphosphat. J. Barth, G. Hochhaus, R. Hochhaus, H. Derendorf and H. Möllmann. Annual Meeting of AGAH, Neuss, (1995)
138. Correlation of *in vitro* and *in-vivo* corticosteroid receptor affinity. S. Rohatagi, G. Hochhaus, H. Derendorf. Eastern Regional Meeting of the American Association of Pharmaceutical Scientists, New Brunswick, (1995)
139. Liposomes as a targeted delivery system to the lung. S. Suarez, G. Hochhaus, R. Gonzalez-Rothi, A. Lukyanov, H. Derendorf, H. Schreier, T. Dalla Costa. GRASP Meeting, New York, (1995)
140. Liposomes as a targeted drug delivery system to the lungs. R. Gonzalez-Rothi, S. Suarez, A. Lukyanov, H. Derendorf, H. Schreier, T. Dalla Costa, G. Hochhaus. Southeast Regional Meeting of the American Association of Pharmaceutical Scientists, Morrisville, (1995)
141. Optimizing dosing time of systemic corticosteroid administration using PK/PD modeling. S. Rohatagi, G. Hochhaus, H. Derendorf. Southeast Regional Meeting of the American Association of Pharmaceutical Scientists, Morrisville, (1995)
142. Receptor based integrated pharmacokinetic modeling of corticosteroids. S. Rohatagi, H. Möllmann, J. Barth, G. Hochhaus, H. Derendorf. Southeast Regional Meeting of the American Association of Pharmaceutical Scientists, Morrisville, (1995)

143. Pharmacokinetics and pharmacodynamics of cloprednol. S. Rohatagi, H. Möllmann, J. Barth, G. Hochhaus, H. Derendorf. Southeast Regional Meeting of the American Association of Pharmaceutical Scientists, Morrisville, (1995)
144. Liposomes as a targeted drug delivery system to the lungs. R. Gonzalez-Rothi, S. Suarez, A. Lukyanov, H. Derendorf, H. Schreier, T. Dalla Costa, G. Hochhaus. 10th Annual Meeting of the American Association of Pharmaceutical Scientists, Miami, (1995)
145. Optimizing dosing time of systemic corticosteroid administration using PK/PD modeling. S. Rohatagi, G. Hochhaus, H. Derendorf. 10th Annual Meeting of the American Association of Pharmaceutical Scientists, Miami, (1995)
146. Receptor based integrated pharmacokinetic and pharmacodynamic modeling of corticosteroids after single and multiple administration. S. Rohatagi, H. Möllmann, J. Barth, G. Hochhaus, H. Derendorf. 10th Annual Meeting of the American Association of Pharmaceutical Scientists, Miami, (1995)
147. Pharmacokinetics and pharmacodynamics of cloprednol. S. Rohatagi, H. Möllmann, J. Barth, G. Hochhaus, H. Derendorf. 10th Annual Meeting of the American Association of Pharmaceutical Scientists, Miami, (1995)
148. Pharmacokinetic and pharmacodynamic modeling of budesonide after single and multiple oral administration. P. Fröhlich, H. Möllmann, H. Derendorf, G. Hochhaus. 10th Annual Meeting of the American Association of Pharmaceutical Scientists, Miami, (1995)
149. PK/PD based characterization of pulmonary targeting of glucocorticoids. G. Hochhaus, S. Suarez, R. Gonzalez-Rothi, H. Derendorf, T. Dalla Costa. IBC International Conference on Pharmacokinetic/Pharmacodynamic Analysis, Washington, (1996)
150. Disposition and blood cell effects of prednisolone and methylprednisolone. S. Rohatagi, G. Hochhaus, H. Möllmann, J. Barth, H. Derendorf. 97th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Orlando, (1996)
151. Receptor-based integrated pharmacokinetic and pharmacodynamic evaluation of corticosteroids. H. Derendorf, S. Rohatagi, G. Hochhaus, J. Barth, H. Möllmann. VI World Conference on Clinical Pharmacology and Therapeutics, Buenos Aires, (1996)
152. Ultra-high dosed methylprednisolone in acute spinal cord injury (SCI) - pharmacokinetics and effects on cortisol, potassium, glucose and blood cells. J. Barth, H. Möllmann, A. Möllmann, M. Krieg, U. Bötzel, G. Hochhaus, H. Derendorf. VI World Conference on Clinical Pharmacology and Therapeutics, Buenos Aires, (1996)
153. Pharmacokinetics of prednicarbate after dermal, oral and pulmonary administration and monitoring of potential side effects. J. Barth, H. Möllmann, G. Lehr, T. Höhler, H. Derendorf, G. Hochhaus. 6th Annual Meeting of the German Society for Clinical Pharmacology and Therapeutics, Dresden, (1996)
154. Pharmacokinetic/pharmacodynamic relationships relevant for optimizing the effect/risk ratios after topical administration - Pulmonary delivery as an example. G. Hochhaus, R. Gonzalez-Rothi, H. Derendorf, H. Schreier, H. Möllmann. 6th Annual Meeting of the German Society for Clinical Pharmacology and Therapeutics, Dresden, (1996)
155. Pharmacokinetics and -dynamics after application of budesonide pH-modified-release capsules in patients with Crohn's disease and healthy volunteers. A. Tromm, H. Möllmann, S.V. Heymann, J. Barth, B. May, G. Hochhaus, H. Derendorf. 6th Annual Meeting of the German Society for Clinical Pharmacology and Therapeutics, Dresden, (1996)

156. Modulation of lymphocyte count in blood by the circadian rhythm of endogenous cortisol. B. Meibohm, G. Hochhaus, H. Möllmann, J. Barth, H. Derendorf. 25th Annual Meeting of the American College of Clinical Pharmacology, Philadelphia, (1996)
157. Cumulative cortisol suppression as a measure of the systemic effect of inhaled corticosteroids. B. Meibohm, G. Hochhaus, H. Möllmann, J. Barth, H. Derendorf. 25th Annual Meeting of the American College of Clinical Pharmacology, Philadelphia, (1996)
158. Pharmacokinetic/pharmacodynamic evaluation of budesonide after oral delivery. G. Hochhaus, H. Möllmann, M. Krieg, A. Möllmann, A. Tromm, H. Derendorf, J. Barth. 25th Annual Meeting of the American College of Clinical Pharmacology, Philadelphia, (1996)
159. The effect of dose and release rate on pulmonary targeting of glucocorticoids using liposomes as a model dosage form. S. Suarez, R. Gonzalez-Rothi, G. Hochhaus. 11th Annual Meeting of the American Association of Pharmaceutical Scientists, Seattle, (1996)
160. Circadian rhythm of lymphocytes in blood and its interrelation to endogenous cortisol. B. Meibohm, G. Hochhaus, H. Möllmann, J. Barth, H. Derendorf. 11th Annual Meeting of the American Association of Pharmaceutical Scientists, Seattle, (1996)
161. Pharmacokinetics of inhaled glucocorticoids. H. Derendorf, G. Hochhaus, B. Meibohm, H. Möllmann, J. Barth. Workshop on Inhaled Glucocorticoids, Brussels, (1997)
162. Stability of Budesonide and Triamcinolone Acetonide in Nebulizer Solution. J. Talton, L. Hendeles, G. Hochhaus. Poster, SEAAPS Conference (1997).
163. Pharmacokinetics of inhaled glucocorticoids. Derendorf, G. Hochhaus, B. Meibohm, H. Möllmann, J. Barth Landmark Symposium London, (1997)
164. Time dependency of the pharmacologic response to glucocorticoids. 98th Annual Meeting of the Am. Soc. Clin. Pharmacology & Therapeutics. San Diego, (1997)
165. Pharmacokinetics and pharmacodynamics of soft corticosteroids for inhalation. H. Derendorf, G. Hochhaus, B. Meibohm, H. Möllmann, J. Barth. 1st Drug Optimization via Retrometabolism Conference, Amelia Island, (1997)
166. PK/PD-modeling of the circadian rhythm of the lymphocyte count in blood modulated by endogenous cortisol 1st Drug Optimization via Retrometabolism Conference. B. Meibohm, G. Hochhaus, H. Möllmann, J. Barth, H. Derendorf, Amelia Island, (1997)
167. PK/PD-approach to assess the systemic activity of inhaled corticosteroids as cumulative cortisol suppression. B. Meibohm, G. Hochhaus, H. Möllmann, J. Barth, H. Derendorf. 1st Drug Optimization via Retrometabolism Conference, Amelia Island, Ma (1997)
168. The effects of dose and release rate on pulmonary targeting. S. Suarez, R. Gonzalez-Rothi, H. Schreier, G. Hochhaus. 1st Drug Optimization via Retrometabolism Conference, Amelia Island, (1997)
169. Receptor binding studies of soft anticholinergics. F. Huang, G. Hochhaus, N. Bodor. 1st Drug Optimization via Retrometabolism Conference, Amelia Island, (1997)
170. An AM1-based model for the estimation of the relative binding affinity for glucocorticoids.M.-J. Huang, S. Tamada, G. Hochhaus, N. Bodor. 1st Drug Optimization via Retrometabolism Conference, Amelia Island, (1997)

171. Predictive power of PK/PD –modeling for inhaled glucocorticoids. B. Meibohm, G. Hochhaus, H. Möllmann, J. Barth, H. Derendorf. American College of Clinical Pharmacology. 16th Annual Meeting, Phoenix, (1997)
172. Advanced PK/PD model for the modulation of lymphocyte count by glucocorticoids and endogenous cortisol. B. Meibohm, G. Hochhaus, H. Möllmann, J. Barth, H. Derendorf. American College of Clinical Pharmacology. 16th Annual Meeting, Phoenix, (1997)
173. Algebraic solutions for non-linear protein binding interactions. S. Rohatagi, G. Hochhaus, A. Kovar, H. Derendorf. American College of Clinical Pharmacology. 16th Annual Meeting, Phoenix, (1997)
174. Basic concepts in pulmonary targeting. G. Hochhaus. American College of Clinical Pharmacology. 16th Annual Meeting, Phoenix, (1997)
175. Pharmacokinetic/Pharmacodynamic aspects of asthma therapy. G. Hochhaus, Physiological Science Seminar 1997, Gainesville, (1997)
176. Pharmacokinetic/Pharmacodynamic aspects of pulmonary targeting of inhaled glucocorticoids. G. Hochhaus, Pharmacy Science Seminar, Richmond. (1997)
177. Pharmacokinetics and pharmacodynamics after inhaled administration of flunisolide. M. Wagner, R. Stöckmann, H. Derendorf, G. Hochhaus, B. Meibohm, J. Barth M. Krieg. XVI International Congress of Allergology & Clinical Immunology, Cancun, (1997)
178. Pharmacokinetics and pharmacodynamic evaluation after single-dose inhaled fluticasone propionate. H.W. Möllmann, M. Wagner, R. Stöckmann, H. Derendorf, B. Meibohm, M. Krieg, G. Hochhaus,. XVI International Congress of Allergology & Clinical Immunology, Cancun, (1997)
179. Pharmacokinetic/pharmacodynamic evaluation of systemic effects of flunisolide after inhalation. H. Möllmann, H. Derendorf, J. Barth, B. Meibohm, M. Wagner, M. Krieg, A. Möllmann, G. Hochhaus. 12th Annual Meeting of the American Association of Pharmaceutical Scientists, Boston, November (1997). Pharm Res. 14, S-140 (1997)
180. Pharmacokinetic/pharmacodynamic evaluation of systemic effects of inhaled glucocorticoids. G. Hochhaus, H. Derendorf, B. Meibohm. Pharm Res. 14, S-140 (1997)
181. Chronopharmacology of cortisol suppression during inhaled corticosteroid therapy. B. Meibohm, G. Hochhaus, H. Möllmann, J. Barth and H. 12th Annual Meeting of the American Association of Pharmaceutical Scientists, Boston, November (1997). Pharm Res. 14, S-141 (1997)
182. Absorption profiles of inhaled corticosteroids. B. Meibohm, G. Hochhaus, H. Möllmann, J. Barth and H. Derendorf. 12th Annual Meeting of the American Association of Pharmaceutical Scientists, Boston, November (1997). Pharm Res. 14, S-141 (1997)
183. Pharmacokinetic/Pharmacodynamic evaluation of systemic effects of inhaled glucocorticoids G. Hochhaus, H. Derendorf, B. Meibohm. 12th Annual Meeting of the American Association of Pharmaceutical Scientists, Boston, November (1997). Pharm Res. 14, S-140 (1997)
184. Pharmacokinetic/pharmacodynamic evaluation of systemic effects of budesonide after oral delivery. G. Hochhaus, B. Meibohm, H. Moellmann, H. Derendorf, J. Barth, M. Wagner, M. Krieg, J. Knoeller. 12th Annual Meeting of the American Association of Pharmaceutical Scientists, Boston, November (1997). Pharm Res. 14, S-617 (1997)
185. Basic principles of pulmonary targeting. G. Hochhaus. 31st Annual Higuchi Research Seminar, Lake Ozark (1998)

186. Pulmonary targeting of inhaled glucocorticoids: How is it influenced by formulation? G. Hochhaus, S. Suarez, R.J. Gonzalez-Rothi, H. Schreier. Respiratory Drug Delivery VI. Hilton Head, South Carolina (1998)
187. Assessment of pulmonary selectivity of triamcinolone acetonide powders using an ex vivo receptor binding assay. S. Suarez, J.D. Talton. G. Hochhaus. Respiratory Drug Delivery VI. Hilton Head, South Carolina (1998)
188. Pharmacokinetic-Pharmacodynamic modeling of cumulative cortisol suppression by inhaled corticosteroids. H. Derendorf, B. Meibohm, H. Moellmann, J. Barth, M. Wagner, M. Krieg, R. Stoeckmann. 8th International conference on Pharmaceutical Technology, Paris (1998)
189. Effect of formulation aspects on pulmonary targeting of glucocorticoids . G. Hochhaus, S. Suarez, J. Talton, R.J. Gonzalez-Rothi. 8th International conference on Pharmaceutical Technology, Paris (1998)
190. Effect of clearance and volume of distribution on pulmonary targeting of inhaled glucocorticoids. G. Hochhaus, H. Derendorf, B. Meibohm. Measurement and Kinetics of in vivo drug effects Advances in simultaneous pharmacokinetic/pharmacodynamic modeling. Noordwijkerhout, The Netherlands (1998)
191. Interaction between endogenous and exogenous corticosteroids and blood lymphocytes: The buffering capacity of cortisol suppression. G. Hochhaus, B. Meibohm, J. Stark, H. Moellmann, H. Derendorf, M. Wagner. Measurement and Kinetics of in vivo drug effects Advances in simultaneous pharmacokinetic/pharmacodynamic modeling. Noordwijkerhout, The Netherlands (1998)
192. Mechanism based PK/PD model for the interaction between endogenous and exogenous corticosteroids and blood lymphocytes. B. Meibohm, H. Derendorf, H. Moellmann, M. Wagner, G. Hochhaus. Measurement and Kinetics of in vivo drug effects Advances in simultaneous pharmacokinetic/pharmacodynamic modeling. Noordwijkerhout, The Netherlands (1998)
193. Chronopharmacological aspects in cortisol suppression during inhaled corticosteroid therapy. B. Meibohm, G. Hochhaus, H. Moellmann, J. Barth, H. Derendorf. Measurement and Kinetics of in vivo drug effects Advances in simultaneous pharmacokinetic/pharmacodynamic modeling. Noordwijkerhout, The Netherlands (1998)
194. Release characteristics of budesonide from pH-modified release capsules and controlled ileal release capsules. H.W. Moellmann, M. Wagner, A. Tromm, A.C. Moellmann, S. Homrighausen, J. Barth, M. Krieg, G. Hochhaus. American Gastroenterological Association and American Association for the study of Liver Disease. New Orleans (1998)
195. Interaction between endogenous and exogenous corticosteroids and blood lymphocytes: The buffering capacity of cortisol suppression. G. Hochhaus, B. Meibohm, J. Stark, H. Moellmann, H. Derendorf, M. Wagner. American College of Clinical Pharmacology. 17th Annual Meeting, Toronto (1998)
196. Pharmacokinetic/pharmacodynamic relationships for β_2 -adrenergic drugs. G. Hochhaus. American College of Clinical Pharmacology. Tanabe Young Investigator recipient lecture. 17th Annual Meeting, Toronto (1998)
197. Dynorphin A1-13 derivatives with enhanced metabolic stability. S. I. Al-Fayoumo, E. Mulder, G. Hochhaus, 13th Annual Meeting of the American Association of Pharmaceutical Scientists, San Francisco, November (1998). Pharm Sci. 1, S-38 (1998)
198. Pulmonary targeting of intratracheal triamcinolone acetonide dry-powder using an ex-vivo receptor binding assay. J. D. Talton, S. Suarez, R. Gonzales-Rothi, G. Hochhaus, 13th Annual Meeting of the American Association of Pharmaceutical Scientists, San Francisco, November (1998). Pharm Sci. 1, S-63 (1998)

199. Pulmonary targeting of intratracheal fluticasone propionate dry-powder vs. intravenous solution using an ex-vivo receptor binding assay. J. D. Talton, S. Suarez, R. Gonzales-Rothi, G. Hochhaus, 13th Annual Meeting of the American Association of Pharmaceutical Scientists, San Francisco, November (1998). Pharm Sci. 1, S-63 (1998)
200. A novel assay for the pharmacokinetic/pharmacodynamic analysis of gene delivery in vitro. B.E. Houk, G. Hochhaus, J.A. Hughes, 13th Annual Meeting of the American Association of Pharmaceutical Scientists, San Francisco, November (1998). Pharm Sci. 1, S-471 (1998)
201. Pulsed laser deposited polymer films onto pulmonary dry powders for improved drug delivery. J. Talton, G. Hochhaus, J. Fitz-Gerald, R. Singh. MRS 1998 Fall Meeting, Boston, MA (1998), p 597
202. Investigations on the pulmonary effect-time profile after inhalation of fluticasone propionate. M. Wagner, G. Hochhaus, A.C. Moellmann, M. Krieg, H. Derendorf, H.W. Moellmann. 171th Meeting of the ‘Rheinisch Westfaelische Gesellschaft fuer Innere Medizin’ Duesseldorf (November 1998).
203. Rectal Application of Budesonide foam: A therapeutic advantage?. M. Koelsch, M. Wagner, H. Dimova, G. Hochhaus, A.C. Moellmann, H. Derendorf, H.D. Tauschel, B. May, A. Tromm, H.W. Moellmann. 171th Meeting of the ‘Rheinisch Westfaelische Gesellschaft fuer Innere Medizin’ Duesseldorf (November 1998).
204. Pharmacokinetic/pharmacodynamic evaluation of inhaled glucocorticoids. MUSC, College of Pharmacy, Charleston (October 1998)
205. Pharmacokinetic/pharmacodynamic evaluation of inhaled antiasthmatic agents. G. Hochhaus, University of Colorado, College of Pharmacy, Denver, (January 1999)
206. A physiological Pharmacokinetic (PK) model for beclomethasone dipropionate (BDP) delivered via conventional metered dose inhaler (MDI) and Spiros, an investigational dry powder inhaler (DPI). G. Hochhaus, S. Scranton, LM Vaughan, M. Hill. AAAAI 55th Annual Meeting, Orlando (1999), J. Allergy Clin. Immunol. 103, S135 (1999)
207. Synthesis of Biodegradable Poly(lactic-co-glycolic acid) Films by Pulsed Laser Deposition. J. Talton, G. Hochhaus, J. Fitz-Gerald, R. Singh, Presentation, Materials Research Society, Spring (1999).
208. Factors Influencing Pulmonary Targeting. G. Hochhaus, Boehringer Ingelheim, Ridgefield CT, (May 1999)
209. Pulmonary Targeting of commercially Inhaled glucocorticoids. G. Hochhaus, Retrometabolism Based Drug Design and Conference, Amelia Island Plantation, FL (May 1999)
210. Loteprednol Etabonate - A Soft Steroid for the Treatment of Allergic Diseases of the Airways. S. Szelenvi, G. Hochhaus, H. Dimova, S. Krishnaswami and J. Engel, Retrometabolism Based Drug Design and Conference, Amelia Island Plantation, FL (May 1999)
211. Optimized therapeutic Ratio of Inhaled Corticosteroids Using Retrometabolism. H. Derendorf, G. Hochhaus, S. Krishnaswami, H. Moellman,, Retrometabolism Based Drug Design and Conference, Amelia Island Plantation, FL (May 1999)
212. Pharmacokinetics of plasmid DNA in vitro and after IV bolus administration in the rat. B.E. Houk, G. Hochhaus, J.A. Hughes, Southeast Regional Meeting of the American Association of Pharmaceutical Scientists, Durham, NC (1999)
213. Pharmacokinetic/Dynamic considerations for the topical and systemic lung delivery of glucocorticoids and proteins. G. Hochhaus, Southeast Regional Meeting of the American Association of Pharmaceutical Scientists, Durham, NC (1999)

214. Pulmonary Targeting: What is important. G. Hochhaus, University of Halle, Halle, Germany (June 1999)
215. Pulmonary targeting of inhaled glucocorticoids. G. Hochhaus. 2nd Symposium on New Developments in Clinical Pharmacy and Clinical Pharmacology, Reims, France (June, 1999)
216. Pharmacokinetics/Pharmacodynamics of budesonide foam after single and multiple dosing. H.W. Möllmann, M. Wagner, A.C. Möllmann, X Koelsch, H. Dimova, Y. Tang, A. Tromm, H.-D. Tauschel, M. Krieg, H. Weisser, H. Derendorf, G. Hochhaus, 28th Annual Meeting of the American College of Clinical Pharmacology, Washington (1999), *J. Clin Pharmacol.* 39, 985 (1999)
217. Pharmacokinetics of fluticasone propionate (FP) after single and bidaily inhaled administration over 5 days. M. Wagner, G. Hochhaus, H. Derendorf, Y. Tang, A.C. Moellmann, M. Krieg, H.W. Moellmann 28th Annual Meeting of the American College of Clinical Pharmacology, Washington (1999), *J. Clin Pharmacol.* 39, 985 (1999)
218. PK/PD workshop. Guenther Hochhaus, ESCP 28th Symposium on clinical pharmacy, Berlin 1999
219. Pharmacokinetic/pharmacodynamic modeling of lymphocyte subpopulations after oral budesonide administration. S. Werner, J. Stark, H. Moellmann, S. Homrighausen, H. Derendorf, G. Hochhaus, M. Krieg. 14th Annual Meeting of the American Association of Pharmaceutical Scientists, New Orleans, November (1999). *Pharm Sci.* 1, Issue 4, # 1060 (1999)
220. Determination of fluticasone propionate in human plasma by liquid chromatography-tandem mass spectrometry. S. Krishnaswami, H. Möllmann, H. Derendorf, G. Hochhaus. 14th Annual Meeting of the American Association of Pharmaceutical Scientists, New Orleans, November (1999). *Pharm Sci.* 1, Issue 4, # 2017 (1999)
221. Pharmacokinetics of plasmid DNA in vitro and after Iv bolus administration in the rat. B.E. Houk, G. Hochhaus, J.A. Hughes. 14th Annual Meeting of the American Association of Pharmaceutical Scientists, New Orleans, November (1999). *Pharm Sci.* 1, Issue 4, # 3155 (1999)
222. Pharmacokinetics of fluticasone propionate after single and multiple inhalations. S. Krishnaswami, H. Möllmann, G. Hochhaus, M. Wagner, R. Stöckmann, H. Derendorf. 14th Annual Meeting of the American Association of Pharmaceutical Scientists, New Orleans, November (1999). *Pharm Sci.* 1, Issue 4, # 3167 (1999)
223. Plasma concentrations and pulmonary targeting of budesonide after intravenous and intratracheal administration in rats. J.D. Talton, G. Hochhaus. 14th Annual Meeting of the American Association of Pharmaceutical Scientists, New Orleans, November (1999). *Pharm Sci.* 1, Issue 4, # 3669 (1999)
224. Characterization of biodegradable poly(lactic-co-glycolic acid) coatings on budesonide using pulsed laser deposition. J.D. Talton, J.M. Fitz-Gerald, R. Singh, G. Hochhaus. 14th Annual Meeting of the American Association of Pharmaceutical Scientists, New Orleans, November (1999). *Pharm Sci.* 1, Issue 4, # 3671 (1999)
225. Pulmonary targeting of poly(lactic-co-glycolic acid) coated budesonide dry powders vs uncoated powders using an ex vivo receptor binding assay in rats. J.D. Talton, J.M. Fitz-Gerald, R. Singh, G. Hochhaus. 14th Annual Meeting of the American Association of Pharmaceutical Scientists, New Orleans, November (1999). *Pharm Sci.* 1, Issue 4, # 3672 (1999)
226. Computer simulations for assessing pulmonary targeting. G. Hochhaus. Airway activity and selectivity of inhaled steroids (IS) in asthma- Mechanism, models of evaluation and clinical impacts. Palm Beach, Florida, December 1-3, 1999

227. How does PK/PD modeling affect the selection of a dose. G. Hochhaus. Accelerating PK/PD drug development: biomarkers & surrogate endpoints, modeling outcomes & toxicity. Washington, DC, January 27-28, 2000
228. Streamlining dosing requirements with mechanism-based PK/PD modeling. G. Hochhaus. Clinical pharmacokinetics and pharmacodynamics. Arlington, VA, February 28-29, 2000
229. Coating of Steroid Particles. G. Hochhaus. Recent advantages in pressurized inhalers. London, UK, March 2-3, 2000
230. Pharmacokinetic/Pharmacodynamic aspects of pulmonary delivery of liposomes. G. Hochhaus 7th Liposome Research Days Conference. Napa Valley. April 12-15, 2000.
231. Nano-thin coatings for improved lung targeting of glucocorticoid dry powders: In-vitro and In-vivo characteristics. J. Talton, J. Fitz-Gerald, R. Singh, G. Hochhaus. Respiratory Drug Delivery VII, Tarpon Springs, May 14-18, 2000
232. Fluticasone propionate (FP) plasma concentrations in children with asthma. O. Bessmertny, J. Liang, G. Hochhaus, S. Chesrown, L. Hendeles. ATS 2001, San Francisco, CA May 18-23, 2001.
233. Effect of Holding Chambers on *In Vitro* Respirable Dose of Fluticasone from a Metered-Dose Inhaler M. J. Asmus, Z. M. Liang, I. Coowanitwong, G. Hochhaus 2000 AAPS Annual Meeting, Indianapolis, IN. 2000. AAPS PharmSci Supplement 2000;2(4), available at http://www.aapspharmaceutica.com/scientificjournals/pharmsci/am_abstracts/2000/627.html
234. Pharmacokinetic/Pharmacodynamic Modeling of Inhaled Fluticasone Propionate S. Krishnaswami, G. Hochhaus, H. Moellmann, M. Wagner, R. Stockmann, H. Derendorf, 2000 AAPS Annual Meeting, Indianapolis, IN., Nov. 2000.
235. Effect of Spacers on *In-Vitro* Respirable Dose of Fluticasone Propionate From a Metered-Dose Inhaler M. J. Asmus, Z. M. Liang, I. Coowanitwong, G. Hochhaus, 2000 AAPS Annual Meeting, Indianapolis, IN., 2000. AAPS PharmSci Supplement 2000;2(4), available at http://www.aapspharmaceutica.com/scientificjournals/pharmsci/am_abstracts/2000/906.html
236. Simultaneous Determination of the Glucocorticoid Soft Drug Loteprednol Etabonate, PJ91 and Cortisol in Plasma by Liquid Chromatography-Tandem Mass Spectrometry H. G. Dimova, S. Krishnaswami, G. Hochhaus, 2000 AAPS Annual Meeting, Indianapolis, IN., Nov. 2000.
237. Interplay of Endogenous and Exogenous Corticosteroids and the Effects on Blood Lymphocytes J. G. Stark, H. Derendorf, H. Mollmann, G. Hochhaus, 2000 AAPS Annual Meeting, Indianapolis, IN., Nov. 2000.
238. Sustained Release Formulations of Rifampin for Inhalation Therapy I. Coowanitwong, J. D. Talton, R. Singh, J. A. Hughes, G. Hochhaus, J. M. Fitz-Gerald, 2000 AAPS Annual Meeting, Indianapolis, IN, Nov. 2000
239. Stabilization of cellular membranes by glucocorticosteroids: demonstration of dose-dependency in an ex vivo/in vitro model using human erythrocytes. J. Barth, M. Cziborra, H.W. Moellmann, D. Jaeger, G. Hochhaus. ACJ International, Suppl 2:11, 2000. XVII International Congress of Allergology & Clin. Immunology. South Australia, Oct. 2000.
240. Pharmacokinetics of fluticasone propionate (FP) after inhalation into the lung and nose. A.C. Moellmann, M. Wagner, G. Hochhaus, H. Derendorf, H. Dimova, S. Krishnaswami, M. Krieg, H.W. Moellmann. ACJ International, Suppl 2:11, 2000. XVII International Congress of Allergology & Clin. Immunology. South

- Australia, Oct. 2000.
241. Endogenous cortisol after inhalation of fluticasone propionate and budesonide over 5 days. M. Wagner, G. Hochhaus, A.C. Möllmann, H. Derendorf, R. Stöckmann, M. Krieg, J. Barth, H.W. Möllmann. ACJ International, Suppl 2:119, 2000. XVII International Congress of Allergology & Clin. Immunology. South Australia, Oct. 2000.
 242. PK/PD modeling : Does it have a future in drug development. AGAH Annual Meeting 2001. Dresden, Germany, February 2001.
 243. Home-made spacer *in vitro* performance with a fluticasone metered dose inhaler. M.J. Asmus, J. Kiang, I. Coowanitwong, G. Hochhaus, 57th Annual Meeting AAAAI, New Orleans, LA, March 16-21, 2001.. J. Allergy Clin Immunol. 107, S103, 2001
 244. Comparison of aerochamber and aerochamber-plus valved holding chamber *in vitro* performance with a fluticasone metered dose inhaler. J. Liang, M.J. Asmus, I. Coowanitwong, G. Hochhaus, 57th Annual Meeting AAAAI, New Orleans, LA, March 16-21, 2001. J. Allergy Clin Immunol. 107, S103, 2001
 245. Low flow rate *in vitro* performance of fluticasone inhaled delivery systems used in the dice trial, M.J. Asmus, J. Liang, I. Coowanitwong, G. Hochhaus. 57th Annual Meeting AAAAI, New Orleans, LA, March 16-21, 2001. Am. J. Resp. Critical Care, 165, A444 (2001)
 246. Respirable dose of fluticasone from a metered dose inhaler (MDI) and two dry-powder inhalers (DPI). M.J. Asmus, J. Liang, I. Coowanitwong, G. Hochhaus. 57th Annual Meeting AAAAI, New Orleans, LA, March 16-21, 2001. Am. J. Resp. Critical Care, 165, A444 (2001)
 247. *In vitro* performance characteristics of MDI spacers with fluticasone. M.J. Asmus, J. Liang, I. Coowanitwong, G. Hochhaus. 57th Annual Meeting AAAAI, New Orleans, LA, March 16-21, 2001. Am. J. Resp. Critical Care, 165, A444 (2001)
 248. *In vitro* performance characteristics of rigid valved holding chambers (VHC) with fluticasone. M.J. Asmus, J. Liang, I. Coowanitwong, G. Hochhaus. 57th Annual Meeting AAAAI, New Orleans, LA, March 16-21, 2001
 249. Fluticasone propionate (FP) plasma concentrations in children with asthma. O. Bessmertny, J. Liang, G. Hochhaus, S. Chesrown, L. Hendeles. ATS 2001, San Francisco, May 2001.
 250. Attenuation of Gentamicin Induced Nephrotoxicity by Interaction of Strychnine with a Putative Glycine Receptor. A. Arya, S.I. Fayoumi, S. Thamilselvan, S.R. Khan, G. Hochhaus. AAPS, Pharmaceutical Congress of the Americas, Orlando, FL March 24-29, 2001.
 251. Comparison of Two Sustained-Release Inhaled rifampin Formulations Prepared by Pulse Laser Deposition (PLD) and Spray Drying. I. Coowanitwong, J.D. Talton, J.M. Fitz-Gerald, R. Singh, P. Kulvanich, J.A. Hughes, G. Hochhaus. AAPS, Pharmaceutical Congress of the Americas, Orlando, FL March 24-29, 2001.
 252. Pharmacokinetic/Pharmacodynamic Modeling of Budesonide After Oral Administration in Single and Multiple Doses. P.E. Fröhlich, H. Derendorf, G. Hochhaus, B. Meibohm, H. Möllmann. AAPS, Pharmaceutical Congress of the Americas, Orlando, FL March 24-29, 2001.
 253. The Influence of Administration Time on the systemic Effects Observed During Corticosteroid Therapy. J.G. Stark, H. Derendorf, H. Moellmann, G. Hochhaus. AAPS, Pharmaceutical Congress of the Americas, Orlando, FL March 24-29, 2001.

254. Pharmaceutical Considerations for Laser Ablation Based Coatings. G. Hochhaus. Industrial Advisory Board/Science Advisory Board Meeting, Gainesville, FL April 24-25, 2001
255. Laser-Polymer Interactions for Controlled Drug Delivery Systems. V. Craciun, W-S. Kim, I. Coowanitwong, G. Hochhaus, M. Ollinger, K.R. Rau and R.K. Singh. Industrial Advisory Board/Science Advisory Board Meeting, Gainesville, FL April 24-25, 2001
256. Pharmaceutical Considerations for Laser Ablation Based Coatings. G. Hochhaus. Industrial Advisory Board/Science Advisory Board Meeting, Gainesville, FL April 24-25, 2001
257. Pharmaceutical Considerations for Laser Ablation Based Coatings. G. Hochhaus. IFPRI 2001 ERC visit, Gainesville, FL June 6, 2001
258. Comparison of fluticasone aerosol in vitro deposition via Gentle-Haler, Optihaler, and conventual MDI actuator , M.J. Asmus, J. Liang, I. Coowanitwong, G. Hochhaus. *Journal of Aerosol Medicine*, 14, 410 (2001)
259. The effect of volume on in-vitro performance characteristics of an MDI spacer fashioned from plastic cold drink bottle. M.J. Asmus, S. Amburgy, J. Liang, R. Vafadari R., I. Coowanitwong, G. Hochhaus. *Pharmacotherapy* 21, 1295 (2001)
260. Development of a bootstrap procedure for resampling pharmacokinetic data. V. Arya, A. Agarwal, E. Nunan, T. Santos, G. Hochhaus. AAPS Annual Meeting, Denver, CO, Oct. 21-25, 2001.
261. Population pharmacokinetics of methylprednisolone in patients with acute spinal cord injury. J. Kurz, N.V. Nagaraya, S. Balbach, J. Barth, R. Schuhmann, G. Hochhaus, H. Moellmann, H. Derendorf. AAPS Annual Meeting, Denver, CO, Oct. 21-25, 2001.
262. Ultrathin coatings for pulmonary drug delivery. G. Hochhaus, I. Coowanitong, S.-K. Kim, V. Craciun, R. Singh. Presentation, Materials Research Society, Fall (2001) , Boston, November, 2001.
263. Fundamental studies on nanoencapsulated pulmonary drug delivery systems. W.S. Kim, M. Ollinger, V. Craciun, R. Singh, I. Coowanitong, G. Hochhaus, H. Hofmann, R. Houriet, N. Koshizaki. Presentation, Materials Research Society, Fall (2001), Boston, November, 2001.
264. Pharmacokinetic data analysis via bootstrap resampling. V. Arya, A. Agarwal, G. Hochhaus. AAPS Short Course on Computer Simulation and its role in Drug Development Research. Arlington, Virginia, Jan 28-29, 2002
265. The perils of prescription, introduction and case studies, D. Benjamin, G. Hochhaus, AGAH Annual Meeting, Garmisch-Partenkirchen, Jan 27-29, 2002
266. Population Pharmacokinetics/Pharmacodynamics of Ciclesonide. S. Rohatagi, V. Arya, K. Zech, J. Barrett, G. Hochhaus, B. Jensen. AAAAI, 58th Annual Meeting, New York. *J Allergy Clin. Immunol.*, 716 (2002)
267. Clinical Pharmacokinetics and Pharmacodynamics. Building the foundation for optimal predictions of drug design, action and dose (Short course). Institute for International Research, Philadelphia, March 11-12 2002.
268. Common Valved Holding Chamber In-Vitro Performance With a Beclomethasone HFA Metered-Dose Inhaler. Kwon SH, Asmus MJ, Coowanitwong I, Khorsand N, Hochhaus G. *American Journal of Respiratory and Critical Care Medicine*. 2002;165(5):in-press.

269. Relative Amount of Inhaled Fluticasone Delivered to The Airways of Asthmatic Children by Two Similar MDI Chambers. Liang J, Asmus MJ, Hochhaus G, Chesrown SE, Hendeles L. *Journal of Allergy and Clinical Immunology*. 2002;109(1):S242.
270. Approaches to slow release pulmonary drug delivery. Guenther Hochhaus. Particles 2002, Orlando (April 2002)
271. Receptor based PK/PD Modeling. Guenther Hochhaus. 7. Pharmacokinetic/pharmacodynamic Expertentreffen Heiligkreuztal (April 2002)
272. Pulmonary Targeting of Ciclesonide and its active Metabolite as determined in an ex-vivo rat receptor binding assay. G. Hochhaus, J. Talton, M. Stoeck. European Respiratory Society Annual Meeting. Stockholm, October 2002.
273. The Design and Development of the Optimal Inhalation Drug: A PK/PD based discussion. G. Hochhaus. Business and Clinical Developments in Aerosol Therapy. Institute for International Research. Boston, November 2002
274. Inhaled Corticosteroids: Potency vs Efficacy-What really matters. G. Hochhaus. ACAAI. San Antonio, November 2002.
275. Pharmacokinetic/pharmacodynamic evaluations of inhalation drugs. G. Hochhaus. Rio De Janeiro, College of Pharmacology, November 2002.
276. Pharmacokinetic/pharmacodynamic modeling for streamlining drug development. G. Hochhaus. Brazilian Congress of Pharmacology, Aguas de Lindoia, November 2002.
277. Pharmacokinetic/dynamic aspects for targeting drugs to the lung. G. Hochhaus. College of Pharmacy, University of Sao Paulo, Ribeirao Preto, November 2002.
278. Role of p-glycoprotein transporters in the brain permeability of inhaled glucocorticoids. M. Issar, V. Arya, S. Shresta, G. Hochhaus. AAPS Annual Meeting, Toronto, Canada, November, 2002.
279. Pulmonary targeting of beclomethasone dipropionate in rats. Y. Wang, G. Hochhaus. AAPS Annual Meeting, Toronto, Canada, November, 2002.
280. Use of microdialysis to evaluate dexamethasone tissue distribution after oral and topical administration. M. Muller, V.A. Schuck, M. Grant, H. Derendorf, G. Hochhaus. AAPS Annual Meeting, Toronto, Canada, November, 2002.
281. Pulmonary Targeting: What are the critical issues involved? G. Hochhaus. AstraZeneca, 17th December 2002.
282. The clinical relevance of pharmacokinetic and pharmacodynamic data. G. Hochhaus. Current trends in allergic reactions. A multidisciplinary approach to patient care. NIAID/ NIH. Bethesda, Maryland, February 2003.
283. Relative Amount of Inhaled Fluticasone Delivered to The Airways of Asthmatic Children by Two Similar MDI Chambers. Liang J, Asmus MJ, Hochhaus G, Chesrown SE, Hendeles L. *Journal of Allergy and Clinical Immunology*. 2002;109(1):S242.
284. Inhaled Corticosteroids: Pharmacokinetic and Pharmacodynamics. G. Hochhaus. ATS Annual Meeting, Seattle May 19, 2003

285. PK/PD of inhaled Glucocorticoids-New Developments. G. Hochhaus. 4th Retrometabolism based drug design and targeting conference, Palm Coast, May 2003
286. New Developments in Corticosteroids. G. Hochhaus. Congress on inhaled Corticosteroids in the treatment of Asthma, a and COPD. July 2003, New York.
287. An In-Vitro Comparison of Two Non-Electrostatic Valved Holding Chambers with a Fluticasone Metered-Dose Inhaler. Asmus MJ, Arya V, Hochhaus G. *Chest. 2003;124(suppl 4): (in-press)*.
288. In-Vitro Comparison of Fluticasone Respirable Dose from a Metered Dose Inhaler and Three Rigid Valved Holding Chambers. Asmus MJ, Wu K, Arya V, Hochhaus G. *Chest. 2003;124(suppl 4): (in-press)*.
289. S. Sahasranaman, M. Issar, G. Hochhaus. Metabolism of mometasone furoate in rat and human liver, lung and plasma. Retrometabolism Based Drug Design and Targeting Conference, May 2003. Is the binding of inhaled glucocorticoids to the glucocorticoid receptors specific? M. Issar, S. Sahasranaman, G. Hochhaus. Annual Meeting of the American Association of Pharmaceutical Scientists, October 2003.
290. S. Why does mometasone furoate exhibit low systemic exposure after oral inhalation? Sahasranaman, M. Issar, G. Hochhaus. Annual Meeting of the American College of Clinical Pharmacology, September 2003.
291. S. Sahasranaman, M. Issar, G. Toth, G. Horvath, G. Hochhaus. Degradation of mometasone furoate in the lung. Annual Meeting of the American Academy of Allergy, Asthma, and Immunology, March 2004.
292. Differences in selectivity of inhaled glucocorticoids to the glucocorticoid receptor. M. Issar, S. Sahasranaman, G. Hochhaus. Annual Meeting of the American Academy of Allergy, Asthma, and Immunology, March 2004.
293. Optimizing pharmaceutical properties of inhalation drugs. G. Hochhaus. Respiratory Drug Delivery IX, Palm Springs, April 2004
294. Impact of New Anti-Static valved-holding chamber on airway delivery of inhaled fluticasone propionate in asthmatic children. M.J. Asmus, G. Hochhaus, Y. Tang, L.T. Spencer, S.E. Chesrown, L. Hendeles. ATS 2004, Orlando, May 2004.
295. Effect of MDI valved holding chamber antistatic coating on bioavailability of inhaled fluticasone in subjects with asthma. M.J. Asmus, G. Hochhaus, Y. Tang, S.E. Chesrown, L. Hendeles. ATS 2004, Orlando, May 2004.
296. Population Pharmacokinetics of Levofloxacin in a Medical Intensive Care Unit Z. R. Tayab, S. Kaufmann, G. Hochhaus, D. Jager, and J. Barth., American College of Clinical Pharmacology. Phoenix, Arizona. October, 2004.
297. A Sensitive and Specific LC/MS/MS Assay for the Detection of Mometasone Furoate in Human Plasma. Y. Tang, S. Sahasranaman, D. Biniasz, G. Hochhaus. AAPS Annual Meeting, Baltimore, November 2004
298. Pharmacological Properties of the Metabolites of Mometasone Furoate. S. Sahasranaman, M. Issar, G. Hochhaus. AAPS Annual Meeting, Baltimore, November 2004
299. Relative anti-inflammatory potency of corticosteroids measured by AP-1-inhibitory potency. N. Dirks, S.Li, C. Yates, G. Hochhaus, B. Meibohm. AAPS Annual Meeting, Baltimore, November 2004
300. PK/PD of inhaled glucocorticoids. Las Vegas March 2005, Summit Speaker Education

301. Nanothin Coatings for pulmonary delivery: A method to improve the local selectivity of inhalation drugs. G. Hochhaus. FDA Course: "The use of Nanotechnology in New Drug Development." Rockville, March 2005
302. PK/PD Modeling as Tool in per-clinical and clinical Drug Development. Guenther Hochhaus. 19th JSSX, Tokyo, April 2005
303. Is the distribution of glucocorticoids affected by transporters. G. Hochhaus. 5th Retrometabolism Conference. Hakone, Japan, May 2005
304. Pharmacokinetic Evaluation of dosage forms for colonic delivery. Guenther Hochhaus. 32 Annual meeting and exposition of the controlled release society. Miami, June 2005
305. Glucocorticoid transrepression and transactivation potencies as measured by inhibition of AP-1, NF- κ B and activation of GRE. N.L. Dirks, S. Li, G. Hochhaus, C.R. Yates, B. Meibohm. AAPS, Nashville, TN Nov. 2005
306. Effects of the administration time on the cumulative cortisol and lymphocytes suppression of inhaled corticosteroids. K. Wu, J. Stark, H. Derendorf, G. Hochhaus, AAPS, Nashville, TN, Nov. 2005.
307. A pharmacokinetic/pharmacodynamic evaluation of fluticasone propionate and mometasone furoate using adrenal suppression as a surrogate marker. Z.R. Tayab, T.C. Fardon, D.K.C. Lee, K. Haggart, L.C. McFarlane, B.J. Lipworth and G. Hochhaus, AAPS, Nashville, TN, Nov. 2005.
308. ICS Pharmacokinetics: the key for improving Safety and efficacy. Guenther Hochhaus. ACAAI, Annual Scientific meeting. Anaheim November 2005
309. The Science: Advancing Inhaled Corticosteroid Pharmacology. Guenther Hochhaus. Southeastern Allergy Forum, Eastern Allergy Forum, Puerto Vallarta, January 2006

